CLAUS KUSNIERZ-GLAZ, M.D., STANFORD UNIVERSITY MEDICAL CENTER $20,000

CD8+ T Cells and Marrow Transplantation for Lymphoma

Bone marrow transplantation is an important treatment for many cancers. One major obstacle after successful bone marrow transplantation is relapse of the underlying malignancy. Around 10-20% of patients who received their bone marrow from a sibling are suffering from a significant immune reaction, called graft-versus-host disease. The observation that these patients have a decreased relapse rate was named GVL (graft-versus-leukemia or graft-versus-lymphoma) effect. In other words, the donated bone marrow (graft) can not only attack the recipient (host), but also the malignancy.

Preliminary studies in animals show that highly purified donor lymphocytes added to the bone marrow graft of the donor prevent the progressive growth of the leukemia/lymphoma without overt graft-versus-host disease.

Our project deals with a new, modified, but specific protein of the underlying malignancy, in order to immunize the donor to the malignancy and to augment the GVL effect. The capacity to destroy specifically the tumor and to prevent tumor growth is analyzed by an *in vitro* assay and an *in vivo* animal model. We hope that this procedure will prevent the disadvantage of graft-versus-host disease, but maintain the advantage of the GVL effect.

LEUKEMIA RESEARCH FOUNDATION, INC.
899 SKOKIE BLVD., SUITE LL 14, NORTHBROOK, ILLINOIS 60062 • 708/480-1177
FAX 708/480-1417 • 312/275-1177

JANIE WEISENBERG, EXECUTIVE DIRECTOR

Member of: Chicago Association of Commerce and Industry

RESEARCH GRANTS AWARDED FOR 1993 - 1994

The Medical Advisory Board met on May 1, 1993 to review the grant applications and postdoctoral applications which were submitted to our Foundation for consideration this year.

Our thanks to the following doctors who have donated their time and talents to assist us in determining which grant requests should be funded:

Charles M. Rubin, M.D.	***University of Chicago***
Chairman, Medical Advisory Board,	***Leukemia Research Foundation, Inc.***
Douglas Bishop, Ph.D.	*University of Chicago*
Eric G. Bremer, Ph.D.	*Rush Medical College*
John Clancy, Ph.D.	*Loyola Univ., Stritch School of Medicine*
Susan L. Cohn, M.D.	*Children's Memorial Hospital*
Robert Costa, Ph.D.	*The University of Illinois at Chicago*
Alan Diamond, Ph.D.	*University of Chicago*
Leonard C. Erickson, Ph.D.	*Loyola Univ., Stritch School of Medicine*
Alison Finnegan, Ph.D.	*Rush Medical College*
Allen Frankfater, Ph.D.	*Loyola Univ., Stritch School of Medicine*
Howard M. Gebel, Ph.D.	*Rush-Presbyterian-St. Luke's Medical Center*
Mark D. Johnson, Ph.D.	*Northwestern University Medical School*
Timothy W. McKeithan, M.D., Ph.D.	*University of Chicago Medical Center*
J. Bruce Miller, M.D.	*Loyola Univ., Stritch School of Medicine*
Ahmad Safa, Ph.D.	*University of Chicago*
Stephen D. Smith, M.D.	*University of Chicago*
Gregory T. Spear, Ph.D.	*Rush Medical School*
Martin S. Tallman, M.D.	*Northwestern Memorial Hospital*
William Walden, Ph.D.	*University of Illinois at Chicago*

The following procedures was used by our Medical Advisory Board for review and evaluation of the grant applications submitted:

At the meeting, the primary reviewer summarizes the research proposed, discusses the qualifications of the applicant, presents a critique of the application based on the proposal and qualifications of the applicant, and then makes recommendations as to approval and disapproval of the application, priority rating in competition with the other applications and possible modifications in the budget. The secondary reviewer then presents his/her recommendations. Differences of opinion, if any, are discussed and after general discussion of the application, it is rated by each member of the Board. This rating is done by secret ballot by each member and is a numerical rating ranging from 1.0 for the highest evaluation and 5.0 for the lowest evaluation. Primary and secondary reviews do *not* prepare written reviews for distribution. Rather, they need only prepare oral presentations as outlined above.

Each application is given a final score by taking the average of the ratings of the Board members. This is done confidentially by the Foundation's representatives in attendance at the review session. Finally the Chairman of the Foundation's committee prepares a confidential listing, in order of ranking scores, of all the grant applications. Funding is based on these priority ratings.

Representatives at the review from Central Council of the Leukemia Research Foundation were Hollis Brownstein, Chairman, Medical Advisory Committee; and Paul Sanders and Bill Burton, Committee Members.

Descriptions provided by the doctors of the research projects we are funding are presented so you may be informed of the many types of studies being supported by the Foundation. It is through your efforts as fund raisers that this work may go on.

SCOTT A. NESS, Ph.D., NORTHWESTERN UNIVERSITY $35,000

Tissue-Specific Functions of the v-*myb* Oncogene

Leukemias are cancers of the blood, the uncontrolled outgrowth of cells which should be the normal components of our blood and/or lymph. The oncogenes are a class of genes, first discovered in the avian leukemia viruses, which can cause leukemias and other tumors because they interfere with the normal mechanisms for regulating cell growth. This project will study the properties of the *v-myb* oncogene, which can transform and cause the outgrowth of cells which lead to myeloid leukemias. Because *v-myb* encodes a transcription factor, a protein which binds to cellular genes and regulates their expression, it probably transforms cells and induces leukemias by altering the expression of genes which normally would control the growth and/or differentiation of the cells. One of the most interesting features about *v-myb* is that it only causes myeloid leukemias — it is unable to cause solid tumors or other kinds of leukemias. This may be because of some special feature of myeloid cells which the *v-myb* oncogene is able to take advantage of, something which makes such cells especially vulnerable to *v-myb*. We suspect that Myb requires the help of another myeloid-specific transcription factor to turn on *mim-1*. Indeed, the requirement for such a cofactor may be the reason that *v-myb* only causes myeloid leukemias. We have identified another transcription factor called NF-M which is only found in myeloid cells, and which is also required to activate the *mim-1* gene. We propose to study how the Myb and NF-M proteins interact with one another, for example, whether they form a complex. We have also recently found that introducing Myb and NF-M in other cells can cause myeloid genes to be turned on, effectively converting the cells, at least partially, to a myeloid phenotype. We will also test whether this phenomenon is generalized, and if it occurs in human leukemia cells. A better understanding of these processes will be crucial for determining how oncogenes like *v-myb* are able to induce leukemia, and why genes like *mim-1* are expressed in such tissue-specific ways.

DAVID R. BEIER, M.D., Ph.D., BRIGHAM AMD WOMEN'S HOSPITAL $35,000

Screening for Tumor Suppressor Loci in a Transgenic Mouse Model of Lymphoma

Presently there is considerable evidence to suggest that genetic alterations play a significant role in leukemia and lymphoma. In most cases, however, the specific genes that are mutated in these tumors remain unknown. Recent studies have increasingly pointed to the importance of a class of oncogenes called tumor suppressor genes, whose inactivation results in loss of growth control and subsequent neoplastic transformation. I have developed a means to use a transgenic mouse model to test for regions of DNA that may be lost in tumors. Chromosomal regions that are consistently affected have been found in human tumors to contain tumor suppressor genes. Analysis of a mouse lymphoma model reveals the loss of the oncogene *p53* in several tumors. This demonstrates that it is feasible to use this approach for testing transgenic mouse lines which develop hematopoietic cell cancers for tumor suppressor genes that may be unique to these diseases. I propose to screen a large number of tumors from this transgenic line for additional loci that contribute to neoplastic transformation.

TERRY ANN WOODFORD-THOMAS, Ph.D., WASHINGTON UNIVERSITY SCHOOL OF MEDICINE $35,000

Analysis of the Cyclin-Dependent Protein Kinases, cdk2 and cdk5, in the T cell Cycle

Leukemia results from the uncontrolled proliferation of cells of the immune system. Understanding the molecular basis of this disease requires knowledge of the biochemical machinery that controls the cell cycle. This proposal focuses on characterizing proteins from T lymphocytes that function in the regulation of proliferation. Protein kinases which bind to cellular proteins called cyclins, are thought to control cell cycle progression in most tissues. With the exception of $p34^{cdc2}$ (cdk1), this family of proteins have never been described from lymphocytes. We propose to isolate and characterize two of these protein kinases, cdk2 and cdk5, from activated mouse T cells. It is thought that these enzymes, when complexed to specific cyclins that are synthesized in the early stages of the T cell cycle, play an essential role in linking signals generated by external stimuli, such as specific antigen or T cell growth factors with the cell cycle machinery. We propose to examine the expression of these kinases and their associated cyclins, as well as their ability to phosphorylate proteins, as T cells progress from a resting or quiescent state into a proliferating state.

YOJI SHIMIZU, Ph.D., UNIVERSITY OF MICHIGAN MEDICAL SCHOOL $34,963

Regulation of Lymphocyte Adhesion in Normal and Leukemic T Cells

The successful elimination of a foreign challenge by the body is dependent on a coordinated series of interactions between the various cell types in the immune system. Molecules on the cell surface termed integrins allow this cell-to-cell communication to occur, and other molecules on the cell surface regulate interaction. Defects in this regulation inside the cells or in the function of the integrin itself may be responsible for the development of T cell leukemias and other cancers. This project will examine the biochemical processes by which integrins are regulated on T lymphocytes. First, a cell surface molecule designated CD7 regulates integrin function in an undefined way. This proposal will investigate the role of an important class of intracellular enzymes, termed kinases, in the function of the CD7 molecule. Second, one integrin designated LFA-1 does not function in several cell lines derived from patients with T cell leukemia. This project will analyze why this integrin does not function in these leukemia cells. Since cell-to-cell contact and communication is critical in regulating T cell function, a better understanding of the regulatory mechanisms in normal T cells and the problems that seem to occur in tumor cells is necessary in order to devise improved strategies for detection and treatment of leukemias.

RICHARD M. LONGNECKER, B.S., Ph.D., NORTHWESTERN UNIVERSITY $35,000

Biochemical and Genetic Studies of Epstein-Barr Virus Latent Membrane Protein 2

Most cancers result from a multistep process. Viruses can play a significant role in converting a normal cell to a cancer cell. The study of oncogenic viruses has uncovered important aspects of how they control cell growth and key points in cell growth control which are also important in malignancies not caused by viruses. Epstein-Barr Virus (EBV) is an etiological factor in some human lymphomas and carcinomas. Recent experiments have begun to identify the mechanisms by which Epstein-Barr (EBV) alters cell growth. The proposed research will apply molecular genetic and molecular biologic techniques to explore the role of a newly defined EBV gene in lymphocyte growth transformation. Understanding EBV transformation may provide insight for the development of novel therapeutics for EBV related malignancies.

ALAN J. TOWNSEND, Ph.D., BOWMAN GRAY SCHOOL OF MEDICINE $28,100

The Role of Aldehyde Dehydrogenase in Cyclophosphamide Resistance

Treatment of cancer with chemotherapeutic drugs is based on the fact that cancer cells are generally more sensitive to the toxic effects of these drugs than normal cells. However, significant toxicity to normal cells usually also occurs, and this host toxicity limits the drug dosage that can be given. Therapeutic failure occurs when the malignant cells are no more sensitive to the drug than normal cells, and therefore cannot be eradicated with a drug dose that the patient can tolerate. This phenomenon, termed "drug resistance," can be due to several factors, including metabolism of the drug in resistant cells to a chemical form which is no longer toxic. Metabolic detoxification may play a role in resistance of cancer cells to cyclophosphamide (CPA), a drug used to treat leukemias, lymphomas, multiple myeloma, and some solid tumors. The enzyme aldehyde dehydrogenase (ALDH), which is involved in alcohol metabolism, also has the ability to break down aldophosphamide, a key metabolite of CPA. Although ALDH has been found to be increased in cells resistant to CPA, it is not yet clear if this change is the only factor in CPA resistance, or how much effect the increased ALDH alone has on sensitivity of these cells to the drug. This problem has been resolved directly and without ambiguity by transferring previously isolated ALDH genes into cultured cell lines which do not normally express these isoenzymes, and comparing their sensitivity to CPA to that of the original cell lines. The objective of this project is to utilize these transgenic model systems to extend our understanding of the role of ALDH in cellular resistance to CPA and to aid in identification of nontoxic compounds which reverse CPA resistance by selectively inhibiting ALDH isoenzymes. A second goal is to determine whether these natural protective enzymes may be increased in normal cells by growth factors that are normally present in human serum, and by other inducers as well.

KAREN J. COLLEY, Ph.D., UNIVERSITY OF ILLINOIS AT CHICAGO $22,885

Alteration of Cell Surface Glyconjugates in Leukemia and Breast Cancer Cells

A wide variety of sugar chains modify proteins that are found on the surface of cells. The size and type of sugar chains found on cell surface proteins change during development and during the formation of tumors. Generally, these sugar chains will become longer and more complex, and frequently, there will be a higher proportion of a charged sugar called sialic acid. Specific sugar chains have been demonstrated to influence interactions between cells. Long chains of sialic acid (polysialic acid chains) are thought to decrease the interaction of cells and allow their increased migration. This situation would be advantageous during development of organ systems and also would lead to detachment of tumor cells and their migration into surrounding tissue to form new tumors. The long polysialic acid sugar chains observed during development and in cancer have always been associated with a protein called neural cell adhesion molecule or NCAM. These specific sugar chains have always been observed on NCAM, located exclusively on the cell surface, where they could exert their effects on cell-cell interactions. Our laboratory has found that two cancer cell lines, a human breast cancer line and a rat basophillic leukemia cell line, which have a different pattern polysialic acid chain expression than most cancer cells (such as a human small cell lung cancer cell line). In these two cancer cells, the polysialic acid chains are found only in a compartment inside the cell. In addition, we do not see NCAM on the cell surface of these two cancer cell lines. It is possible that the polysialic acid chains are added too early in the lifetime of the proteins and this leads to the retention of cell surface proteins (such as NCAM) inside the cell. The goal of our research is to identify the proteins which are modified by polysialic acid chains and retained inside the human breast cancer cell line and the basophillic leukemia cell line, and determine whether these sugar chains are added prematurely to these proteins leading to their abnormal location inside these cells. It is possible that the pattern (location) of expression of polysialic acid chains determines the interactions cancer cells have with their environment and other cells. This research project should give us tools to predict how other cancer cells interact with surrounding tissues and their environment based on the location of polysialic acid chains in these cells.

MELISSA B. ROGERS, Ph.D., UNIVERSITY OF SOUTH FLORIDA $35,000

Retinoic Acid – Regulated Genes and Differentiation

Vitamin A and its chemical relatives, the retinoids, are important regulators of cell growth and differentiation in a broad array of tissues. Indeed, vitamin A deficiency is clearly associated with premalignant changes and neoplastic development. Retinoic acid (RA) has also been found to reverse the malignancy of several tumor cell lines. More importantly RA treatment can repress acute promyelocytic leukemia (APML), oral cancer and skin cancer. In tumor cell lines, and presumably *in vivo*, RA exerts its effect by activating a cascade of gene expression which culminates in terminal differentiation and the irreversible loss of the neoplastic phenotype. APML repression is particularly interesting because APML is associated with mutation of a gene required for RA-regulated gene expression. Induction and repression of growth factors are central to this process. One embryonal carcinoma cell line, F9, has been very useful for biochemical and molecular studies of differentiation. RA causes the malignant F9 embryonal carcinoma cells to change into benign cells. I found that RA interacts with 2 growth factors, BMP-2 and -4, to alter the differentiation of F9 cells. This work suggested that these BMPs are involved in RA-induced differentiation. I will analyze these interactions, in order to understand how RA induces malignant cells to differentiate into nonproliferating, benign cells. Elucidation of how the BMPs and RA regulate differentiation *in vitro* will contribute to an understanding of how retinoids regulate normal and neoplastic differentiation. More specifically, understanding how retinoids induce differentiation should lead to improved cancer differentiation therapies, like those used to treat APML and oral cancer.

MARK P. BIRKENBACH, M.D., KOVLER LABORATORIES, UNIVERSITY OF CHICAGO $35,000

Analysis of Novel B Lymphocyte Cytokine Receptor, EBI 3

Epstein-Barr Virus (EBV) infects B lymphocytes, which are the antibody-producing cells of the human immune system. This frequently results in the acute infectious mononucelosis syndrome, characterized by a marked increase in the number of peripheral blood lymphocytes, representing both EBV-infected B lymphocytes induced to multiply by the virus, and uninfected immune cells responding to the infection. In addition, EBV is frequently found in human malignant tumors of B lymphocytes, including Burkitt lymphoma and tumors which arise in patients who are immunosuppressed as a result of AIDS or immunosuppressive drug therapy following organ transplantation. Normal peripheral blood B lymphocytes infected with EBV in culture are stimulated to grow and will proliferate indefinitely. It is likely that the mechanisms which allow EBV to form tumors are related to its ability to alter the growth of cells it infects. To elucidate the mechanisms by which EBV induces cells to grow, I have identified nine novel cell genes which are turned on by virus infection. One of these genes, EBI 3, has the structural characteristics of the cytokine receptor family of molecules. Typically, members of this family are present on lymphocyte surfaces and function as critical mediators of immune cell function by receiving regulatory signals from outside the cell. In other cases, these receptors may themselves be secreted by cells to act soluble growth-regulating factors on other immune cells. These facts suggest that EBI 3 may play an important role in EBV-mediated transformation by modulating the growth of infected cells, or altering responses of the immune system against infection. The proposed studies will examine the expression of EBI 3 and its function in normal and EBV-infected lymphocytes. The EBI 3 structure suggests that it represents a secreted molecule. In other cytokine receptors, both secreted and cell surface forms of the same gene product have been identified. Initial experiments will determine whether EBI 3 is expressed on cell surfaces, is secreted as a soluble factor, or exists in both forms. Associated molecules will be identified using the EBI 3 antibodies to retrieve EBI 3 protein molecules under conditions where interactions with other molecules can be stably maintained. Future studies will be directed toward identifying these associated molecules and determining the effects of EBI 3 on lymphocyte growth and functional activity. The proposed experiments should increase our understanding of how lymphocyte growth and immune responses are regulated. It is hoped that through this understanding, the processes which allow lymphocytes to escape normal regulatory mechanisms and grow in uncontrolled fashion may be elucidated. Ultimately, identification of hormones which modulate lymphocyte growth may allow development of novel approaches to treatment of abnormal lymphocyte proliferations such as leukemia and lymphoma.

KENICHI TAKESHITA, M.D., YALE UNIVERSITY SCHOOL OF MEDICINE $35,000

Development of a Leukemia Therapy Using Antisense Oligonucleotides Directed Against Homeobox Genes

Most leukemias are thought to be caused by aberrant expression of certain genes with oncogenic potential. Many of these genes are known to regulate the proliferation of hematopoietic cells, and intuitively, it makes sense that leukemias are caused by aberrant expression of genes which control proliferation. Therefore, uncontrolled expression of such genes causes uncontrolled proliferation of hematopoietic cells, namely leukemia.

Much of the current leukemia therapy rests on chemotherapy. However, in the last few years, a method to directly control the expression of such genes has been achieved for certain oncogenic genes. This technique involves the use of very short single stranded DNA molecules (called antisense oligonucleotides) which recognize specifically the targeted oncogenic gene.

I (and others) have recently identified a new class of genes, homeobox genes, which appear to regulate proliferation of hematopoietic cells. Uncontrolled expression of some homeobox genes may account for some leukemias. I have shown that two, HLX and DLX-1, are expressed in most acute myelogenous leukemia cell lines.

In the research project described here, I intend to determine whether antisense oligonucleotides directed against the HLX and DLX-1 gene can inhibit the growth of leukemia cells *in vitro*. I intend to test their effectiveness against cells obtained from patients with acute and chronic myelogenous leukemias. These studies will show whether or not homeobox antisense oligonucleotides can be used to treat leukemias.

SHAKEEL AHMAD, Ph.D., GEORGETOWN UNIVERSITY $34,996

Regulation of P-Glycoprotein by Protein Kinase C

This study will examine the role of phosphorylation in the modulation of the activity of the multidrug transporter, P-glycoprotein, the product of the *MDR*1 gene. A recombinant protein model system will be employed that utilizes the baculovirus expression of P-glycoprotein in insect cells to study its regulation *in vitro* by protein kinases such as protein kinase C. The positive regulatory effect of phosphorylation on the drug transport and drug binding activities of P-glycoprotein will be examined. These studies should give a clearer understanding of the ability of phosphorylation to increase the activity of P-glycoprotein activity and hence, elevate multidrug resistance, a process that compromises the response of leukemic patients to chemotherapy by a wide variety of structurally unrelated anticancer drugs. This study will also test the ability of protein kinase inhibitors to reverse phosphorylation and the multidrug resistance phenotype and to help define a new class of potential anticancer agents.

POSTDOCTORAL FELLOWSHIP AWARDS

MASANORI HATAKEYAMA, M.D., Ph.D., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH — $20,000

Elucidation of the Regulatory Mechanism for Retinoblastoma Protein Activity by Employing Yeast Cell Cycle Machineries

Inactivation of the retinoblastoma gene (RB) has been implicated in the pathogenesis of a variety of human malignancies including leukemia. The retinoblastoma gene product (pRB) is considered to be a critical negative regulator of cell growth and this pRB function seems to be tightly regulated by cell-cycle dependent modification known as phosphorylation. In this project, the molecular mechanism underlying the pRB phosphorylation, a critical process to neutralize pRB-mediated growth inhibition, will be investigated by employing yeast *Saccharomyces cerevisciae*, a lower eukaryotic microorganism that possesses highly conserved cell cycle machineries throughout evolution. The yeast system in which incisive genetic approaches are available will provide important clues to understand the role of pRB in the cell growth control and the development of cancer.

ISOBEL ANNE WADMAN, Ph.D., UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS — $20,000

The Regulation of TAL1 by Protein Phosphorylation

Patients with T-cell acute lymphoblastic leukemia (T-ALL) face a dismal prognosis characterized by treatment failure and a high mortality rate. Recent studies have shown that alteration of the *TAL1* gene is the most common genetic lesion associated with this form of leukemia. These studies indicate that aberrant activity of the *TAL1* gene product is likely to be a critical factor in the formation of T-ALL. Therefore, it is imperative to identify the mechanisms by which *TAL1* activity is normally regulated and to determine whether the same regulatory mechanisms can be harnessed for improved treatment of T-ALL patients. This project is designed to examine whether the transcriptional activity of *TAL1* is controlled by protein phosphorylation, a regulatory mechanism commonly utilized in biological systems.

#4262 MOLECULAR MECANISMS BRAIN
6/10-15, 1995 SCOTTSDALE, AZ

File

American Society for Neurochemistry, Inc.

Lynn Wecker, Ph.D.
Treasurer

14 November 1995

Dr. George A. Hashim
The Council for Tobacco Research-U.S.A., Inc.
900 Third Avenue
New York, New York 10022

Dear Dr. Hashim:

On behalf of the American Society for Neurochemistry, Inc., I would like to thank The Council for Tobacco Research-U.S.A., Inc. for the generous donation of $1000 to support a symposium entitled "Molecular Mechanisms of Exocytosis in Neurons and Glia" organized by Dr. Steven Pfeiffer to be held at our Annual Meeting in Philadelphia, Pennsylvania, March 2-6, 1996. This donation will enable Dr. Pfeiffer to invite speakers who are outstanding leaders in the field, contributing significantly to the quality of our scientific program.

Again, thank you very much for your kind donation. We sincerely appreciate your contribution and will acknowledge such in our meeting program, which will be sent to you when it becomes available in the spring, 1996.

Sincerely,

Lynn Wecker, Ph.D., Treasurer
American Society for Neurochemistry

cc: Dr. Steven E. Pfeiffer
Department of Microbiology
University of Connecticut Medical School
Farmington, Connecticut 06030-3205

Chair, Dept. of Pharmacology and Therapeutics, University of South Florida College of Medicine
12901 Bruce B. Downs Blvd., MDC Box 9, Tampa, Florida 33612 Phone: 813-974-2543 Fax: 813-974-3081

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Dr. M. W. Anders
Chairman and Professor
Department of Pharmacology
University of Rochester Medical Center
601 Elmwood Avenue
Rochester, N.Y. 14642

Subject: Molecular Mechanisms of the Brain Reward System Re: #4262
Date: June 10-15, 1995
Location: Scottsdale, AZ

Dear Dr. Anders:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The University of Rochester is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file

LP, ROK, Auditors, Administrative Actions

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Dr. M. W. Anders
Chairman and Professor
Department of Pharmacology
University of Rochester Medical Center
601 Elmwood Avenue
Rochester, N.Y. 14642

Subject: Molecular Mechanisms of the Brain Reward System Re: #4262
Date: June 10-15, 1995
Location: Scottsdale, AZ

Dear Dr. Anders:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The University of Rochester is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file

LP, ROK, Auditors, Administrative Actions

UNIVERSITY OF
ROCHESTER
MEDICAL CENTER

SCHOOL OF MEDICINE AND DENTISTRY
DEPARTMENT OF PHARMACOLOGY

95-2c

February 13, 1995

Rec'd Feb 17, 1995

Dr. George A. Hashim
The Council for Tobacco Research
900 Third Ave.
New York, NY 10022

Dear Dr. Hashim:

At the request of the College of Problems of Drug Dependence (CPDD) the Department has organized a symposium entitled "Molecular Mechansism of the Brain Reward System". The CPPD meeting is scheduled for June 10-15, 1995 in Scottsdale, AZ.

Brain Mapping of the Brain Reward System, Donald Woodward, Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Winston-Salem, NC 27183

Molecular Biology of the Dopamine Transporter, Dr. Susan Amara, Vollum Institute Oregon Health Sciences University. Portland, Oregon 97201-3098

Molecular Mechanisms of Drug Reward, Lisa H. Gold, Dept. of Neurophamacology The Scripps Research Institute. 10666 N. Torey Pines Rd. La Jolla, CA 92037

Overview and New Perspectives, Leo G. Abood , Department of Pharmacology, Univeristy of Rochester Medical Center, Rochester, NY 14642

Since travel expenses are not provided for by the CPDD, we would be grateful if The Council for Tobacco Research could provide partial financial support for the symposium.

Sincerely,

M.W. Anders,
Chairman and Professor

601 Elmwood Avenue
Rochester, New York 14642
(716) 275-1679
Fax: (716) 244-9283

#4261 SIGNAL TRANSDUCTION
FALL, 1995 UNIV. OF VA

UNIVERSITY OF VIRGINIA
HEALTH SCIENCES CENTER
DEPARTMENT OF MICROBIOLOGY

file

July 10, 1995

Dr. George A. Hashim
Associate Research Director
The Council for Tobacco Research U.S.A. Inc.
900 Third Avenue
New York NY 10022

Dear Dr. Hashim:

Thank you for your contribution of $1000.00 for the support of the Fall Oncogenes and Mitogens Symposium entitled Signal Transduction in Time and Space. This contribution will be noted in the Symposium program. We would like to extend a personal invitation to you and other members of the Council for Tobacco Research to attend the Symposium on October 12 and 13, 1995. For your information we are enclosing a copy of the program.

Again, thank you for your support.

Sincerely,

Michael J. Weber
Professor of Microbiology

J. Thomas Parsons
Professor of Microbiology

/ecc
enclosure

cc: Wayne Smith

SCHOOL OF MEDICINE, BOX 441, CHARLOTTESVILLE, VIRGINIA 22908, 804-924-5111; FAX: 804-982-1071

ONCOGENES & MITOGENS SYMPOSIUM

"Signal Transduction in Time and Space"

McLeod Hall Auditorium

Session One
Thursday, October 12

1:00 p.m.
Christopher Marshall
Institute of Cancer Research, London
"Signalling through Ras, Raf and MAP kinases"

1:45 p.m.
Erich Nigg
Swiss Inst. for Experimental Cancer Research
" Control of the Vertebrate Cell Cycle"

2:30 p.m.
Coffee Break
McLeod Hall

2:45 p.m.
Charles Rubin
Albert Einstein College of Medicine
"Anchor Proteins for Protein Kinase A"

3:30 p.m.
Robert Singer
University of Massachusetts
"Mechanisms Controlling Nucleic Acid Localization"

Session Two
Friday, October 13

9:00 a.m.
Roger Tsien
University of California, San Diego
" Fluorescence Imaging of Protein Sociology"

9:45 a.m.
James Lechleiter
University of Virginia
"Mitochondrial Localization and the Modulation of Intracellular Ca2+ Signalling"

10:30 a.m.
Coffee Break
McLeod Hall

10:45 a.m.
Robert Malenka
University of California, San Francisco
"Cellular Signals for Synaptic Plasticity"

11:30 a.m.
Paolo Sassone-Corsi
CNRS, Strasbourg
"Rhythmic Transcription, Autoregulatory Loops and the Hormonal Response"

Supported in part by the Markey Center and the Cancer Center
For more information, call 804-924-0435

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Dr. J. Thomas Parsons
Department of Microbiology
University of Virginia Health Science Ctr.
School of Medicine
Box 441
Charlottesville, VA 22908

Subject: Signal Transduction in Time and Space Re: #4261
Date: Fall of 1995
Location: University of Virginia

Dear Dr. Parsons:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to the University of Virginia and is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file
ROK, LP, Administrative Actions, Auditors

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Dr. J. Thomas Parsons
Department of Microbiology
University of Virginia Health Science Ctr.
School of Medicine
Box 441
Charlottesville, VA 22908

Subject: Signal Transduction in Time and Space Re: #4261
Date: Fall of 1995
Location: University of Virginia

Dear Dr. Parsons:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to the University of Virginia and is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file
ROK, LP, Administrative Actions, Auditors

3/21/95
Will send list of speakers + titles.

95-18

Rec'd 3/14/95

UNIVERSITY OF VIRGINIA
HEALTH SCIENCES CENTER
DEPARTMENT OF MICROBIOLOGY

March 3, 1995

George A. Hashim, Ph.D.
Associate Research Director
The Council for Tobacco Research-U.S.A., Inc.
900 Third Avenue
New York NY 10022

Fall of 1995
title in next paragraph

Dear Dr. Hashim:

Each year the University of Virginia Cancer Center sponsors a Fall Symposium on a topic in basic cancer research. Past topics have included: ***Cell Cycles: Signals and Death; Molecular Signaling & Cell Structure; Molecular Biology of Human Cancer; Protein Phosphorylation; The Ras Superfamily; Viruses, Oncogenes and Cancer; Gene Regulation***; and ***Signal Transduction***. We wish to thank you for your prior financial contribution that helped make the 1994 meeting a great success. For this coming fall, we are organizing a symposium on ***Signal Transduction in Time and Space***. Understanding the role of the physical location of the signal transduction machinery and the timing of the signal in controlling decisions involving cell growth and differentiation is among the central contemporary issues in molecular oncology and cell biology, and this symposium should help to coalesce emerging ideas on the topic.

title →

Invitees include James Darnell (*Rockefeller University*), Robert Malenka (*Univ. of California, San Francisco*), Christopher Marshall (*Inst. for Cancer Research, London*), Erich Nigg (*Swiss Inst. for Experimental Cancer Research*), Michael Rosbash (*Brandeis University*), Charles Rubin (*Albert Einstein College of Medicine*), Robert Singer (*Univ. of Massachusetts*), and Roger Tsien (*Univ. of California, San Diego*).

The topics to be discussed range from circadian rhythms to cell cycles and from membrane signals to nuclear responses. We feel that this conference is particularly timely and will help to focus on new ideas important for improvements in therapies for cancer and other pathologies involving abnormal signal transduction. Given the multi-disciplinary nature of the topic and the outstanding quality of the scientific participants, we expect this symposium to be a major event in this rapidly developing field.

We are writing to ask your financial support for this symposium. Funds will be used to partially offset the costs of travel and local expenses of the speakers. We would, of course, acknowledge your contributions in the program and in any advertisements for the Symposium which are prepared subsequent to receiving a commitment from you. In addition, if your scientists wish to attend the Symposium and engage in discussions with the participants, they would be most welcome.

We look forward to hearing from you, and to your support for a stimulating meeting.

Sincerely,

Michael J. Weber
Professor of Microbiology

J. Thomas Parsons
Professor of Microbiology

cc: Harmon McAllister

SCHOOL OF MEDICINE, BOX 441, CHARLOTTESVILLE, VIRGINIA 22908, 804-924-5111; FAX: 804-982-1071

UNIVERSITY OF VIRGINIA
HEALTH SCIENCES CENTER
DEPARTMENT OF MICROBIOLOGY

March 25, 1995

tel # (804) 924-5395
fax # (804) 982-1071
e-mail: jtp@Virginia.EDU

Dr. George A. Hashim
Associate Research Director
The Council for Tobacco Research- U. S. A., Inc.
900 Third Ave.
New York, NY 10022

fax: (212) 421 8898

Dear Dr. Hashim:

Thank you for your recent telephone call regarding our request for support for the University of Virginia's Fall Symposium on **"Signal Transduction in Time and Space"**. Planning for this meeting is progressing well and the following individuals have agree to attend.

Christopher Marshall, Imperial Cancer Research Fund, London: *Temporal and spatial regulation of the MAP kinase pathway.*

Robert Malenka, University of California, San Francisco: *Signal transduction in long-term depression and potentiation.*

Eric Nigg, Swiss Institute for Experimental Cancer Research: *Cyclical and spatial regulation of cdks and cyclins.*

Charles Rubin, Albert Einstein College of Medicine: *Regulatory targeting of protein kinase A in cellular compartments.*

Roger Tsien, University of California, San Diego: *Localization and oscillation of cAMP in cellular regulation.*

Robert Singer, University of Massachusetts Medical School. *Targeting protein synthesis to sub-cellular compartments.*

Unfortunately, Jim Darnell and Mike Rosbash can not attend and we are currently seeking individuals of comparable stature to speak on JAK-Stat signalling and cyclical regulation of gene expression. We are very excited about the topic of this year's Symposium; we feel that all of the speakers are working at the cutting edge of discovery in their respective fields. We anticipate an exciting two days. We look forward to your support for this Symposium.

Sincerely,

J. Thomas Parsons
Professor of Microbiology

SCHOOL OF MEDICINE, BOX 441, CHARLOTTESVILLE, VIRGINIA 22908, 804-924-5111; FAX: 804-982-1071

UNIVERSITY OF VIRGINIA
HEALTH SCIENCES CENTER
DEPARTMENT OF MICROBIOLOGY

March 25, 1995

tel # (804) 924-5395
fax # (804) 982-1071
e-mail: jtp@Virginia.EDU

Dr. George A. Hashim
Associate Research Director
The Council for Tobacco Research- U. S. A., Inc.
900 Third Ave.
New York, NY 10022

fax: (212) 421 8898

Dear Dr. Hashim:

Thank you for your recent telephone call regarding our request for support for the University of Virginia's Fall Symposium on **"Signal Transduction in Time and Space"**. Planning for this meeting is progressing well and the following individuals have agree to attend.

Christopher Marshall, Imperial Cancer Research Fund, London: *Temporal and spatial regulation of the MAP kinase pathway.*

Robert Malenka, University of California, San Francisco: *Signal transduction in long-term depression and potentiation.*

Eric Nigg, Swiss Institute for Experimental Cancer Research: *Cyclical and spatial regulation of cdks and cyclins.*

Charles Rubin, Albert Einstein College of Medicine: *Regulatory targeting of protein kinase A in cellular compartments.*

Roger Tsien, University of California, San Diego: *Localization and oscillation of cAMP in cellular regulation.*

Robert Singer, University of Massachusetts Medical School. *Targeting protein synthesis to sub-cellular compartments.*

Unfortunately, Jim Darnell and Mike Rosbash can not attend and we are currently seeking individuals of comparable stature to speak on JAK-Stat signalling and cyclical regulation of gene expression. We are very excited about the topic of this year's Symposium; we feel that all of the speakers are working at the cutting edge of discovery in their respective fields. We anticipate an exciting two days. We look forward to your support for this Symposium.

Sincerely,

J. Thomas Parsons
Professor of Microbiology

SCHOOL OF MEDICINE, BOX 441, CHARLOTTESVILLE, VIRGINIA 22908, 804-924-5111; FAX: 804-982-1071

#4260 GENES, DEVELOP. & CANCER
AUGUST 26-30,1995 UNIV CA SAN DI

Society for Developmental Biology

9650 Rockville Pike

Bethesda, Maryland 20814-3998

Telephone: 301-571-0647. Fax: 301-530-7049

May 10, 1995

Dr. George A. Hashim
Associate Research Director
The Council for Tobacco Research-USA, Inc
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

On behalf of Dr. Helen Blau (who is currently in Paris) and the **SDB** Board of Trustees I thank you and The Council for Tobacco Research-USA, Inc., for your generous support for the 1995 SDB Annual Symposium, **Gene, Development and Cancer**, to be held in August, at UCSD.

The funds will be used to defray travel expenses for the invited minisymposia speakers, giving priority to the junior investigators. One of **SDB**'s major goals is to foster and promote the participation of young scientists at the Annual Symposium.

Enclosed is the pre-registration package and posters announcing the meeting. Unfortunately due to printing schedule, we were not able to include **The Council for Tobacco Research-USA, Inc.**'s name as one of the sponsors of the symposium. We will, definitely, have your company's name in all the final publications, including the special issue of *Developmental Biology* with the full program and the abstracts of the symposium.

We are happy to provide you two sponsor badges, which will give your representatives access to all the scientific and poster sessions, as well as the evening mixers and the concluding banquet. Please mail back the pre-registration forms with the names of your representatives.

Again, we appreciate your support and look forward to establishing a stimulating working relationship between **The Council for Tobacco Research-USA** and **SDB**. Should you have any question, please feel free to call me directly at (202) 885-2193.

Sincerely,

Ida Chow, PhD
Executive Officer

cc: Dr. Helen Blau, SDB President
Dr. Nadia Rosenthal, Symposium Co-Organizer

Society for Developmental Biology

9650 Rockville Pike

Bethesda, Maryland 20814-3998

Telephone: 301-571-0647. Fax: 301-530-7049

February 24, 1995

Dear Colleagues,

We're delighted to announce the **54th. Annual Meeting of the Society for Developmental Biology**, which will be held on the campus of the University of California in San Diego, August 26 to 30, 1995. **The abstract deadline is April 14, 1995!**

The Society has been working actively to make its Annual Meeting an accessible and relevant forum for modern Developmental Biologists, and we're happy to announce:

* Abstracts submitted (on the enclosed form) will be published in the journal Developmental Biology, providing an easy way to reference your work;
* Dozens of renowned Developmental Biologists will present their latest results using almost every system and approach;
* Submitted abstracts may be selected for either poster or platform presentations (in one of the eight Mini-symposia), and an award will be provided for the best poster by a graduate student and by a postdoctoral fellow;
* Workshops on "Education" and special luncheon sessions on "Diversity Issues", "Minorities Issues" and "Ethical Issues" will be held.

Please remember to submit:

* your abstract forms by the April 14 deadline, to the National Office in Bethesda, MD; no FAX submission will be accepted;
* the pre-registration and housing/meal plan form by July 7, to the National Office in Bethesda, MD;
* enclose stamped, self-addressed postcards for acknowledgement of receipt of the abstract and the registration form (optional); please note that phone inquiries for receipt will not be available.

We hope you will join us in sunny La Jolly next August for an exciting Symposium on **Genes, Development and Cancer**.

With best wishes,

Helen M. Blau
Helen M. Blau, President
Co-organizer

Nadia Rosenthal
Nadia Rosenthal
Co-organizer

Victor Vacquier
Victor Vacquier
Local Organizer

SOCIETY FOR DEVELOPMENTAL BIOLOGY
54th. Annual Symposium

August 26 - 30, 1995
University of California San Diego

SYMPOSIUM REGISTRATION INFORMATION

The Registration Fee for all Symposium Participants includes:

* Entry to all Scientific Sessions
* Entry to Exhibits
* Welcome Reception
* Concluding BBQ Banquet
* Mixers
* Refreshment Breaks
* Program and Abstract Book

HOUSING AND MEAL REGISTRATION INFORMATION

Reasonably priced and comfortable housing is available on the UCSD campus within a short walking distance of the Symposium site. All housing consists of apartments with two or three bedrooms, with shared living room and bathroom. All double rooms have two single beds and are rented as either a single or double room.

Campus housing is sold as a package plan only: four nights starting Saturday night and ending Wednesday noon. The package plan includes four breakfasts, four lunches, and three dinners, all served at a nearby cafeteria. The pre-registration deadline for on-campus housing is July 7, 1995. Registrations received after that date are subject to availability. Refunds are available only for housing/meal plan cancellations made in writing and received by the UCSD Housing Office before August 4, 1995.

Symposium participants who choose to stay on campus have 3 options:

* The **first** option is to have a **single room** in an apartment. With this option you will not share a room with another, but you will have other people occupying the other rooms within the apartment. The cost for this option is **$261** and includes all meals as specified above.
* The **second** option is to have a **double room**. With this option you will share a room with another as well as having other participants in the rooms of the apartment. You may indicate your roommate preference on the registration form or allow us to select your roommate if you have no preference. The cost for this option is **$225** and includes all meals as specified.
* The **third** option is if you bring your family the package plan will be **$405** which includes an **entire apartment** and the **participant's meals**. Other family members may purchase the meal plan as described below.

Guests accompanying the Symposium participants may have their own room or share a room with the Symposium participant. The cost for an **accompanying guest** is as follows:

$180 for a single room without meals
$144 for a double room without meals

A special lunch only package is available for accompanying persons and Symposium participants not staying on campus. The cost of this package is $40 and includes lunch Sunday through Wednesday.

Symposium participants and accompanying guests may stay in campus housing several nights before and after the conference. Room rates for these additional nights are noted on the registration form. Please note: Additional nights do not include meals. The rates given are per person, per night.

RECREATION

All Campus housing is located near University recreation centers which offer an Olympic size pool, racquetball and volleyball courts. Tennis courts are located next to the housing complex (please bring your own racquet and balls). Recreation cards may be purchased for a small fee ($14/single and $26/family in 1994) at the registration desk.

The Pacific Ocean is close by but the campus is located on a bluff so that access is not as direct as one might think. The walk down to La Jolly Shores beach is both spectacular and pleasant. The return uphill walk may be somewhat trying!

The Torrey Pines State Park is about a mile north of campus. The many trails crisscrossing the bluffs within this park offer splendid views of the ocean and coast. The aquarium on the campus of the Scripps Institute of Oceanography is a favorite with children. Just across North Torrey Pines Road is the Glider Port, where hang-gliders take off from the bluffs into the ocean breeze.

WEATHER

The weather in La Jolly in August is usually very pleasant with temperatures around 25° (77°F) and low humidity. Evenings can be cooler, down to 17° (63°F), so a light jacket or sweater may be useful. Informal dress will be the rule at the sessions of the symposium. Occasionally very hot, dry weather (Santa Ana condition) can occur for a few days if the prevailing winds shift and come from the inland deserts. The Pacific Ocean is warm enough for swimming. We suggest you bring along swimwear and a beach towel. You may wish to bring a hat to shield you from the bright sunshine when outdoors.

SOCIETY FOR DEVELOPMENTAL BIOLOGY
54th SYMPOSIUM REGISTRATION FORM
August 26-30, 1995

Participant Information

Mr./ Ms./ Dr./ Family Name _____ First Name _____

Institution _____ Department _____

Mailing Address _____

_____

Telephone _____ FAX _____ e-mail _____

Female _____ Male _____ (Please check one to assist with housing assignments)

Symposium Registration

		By 7/7/95	After 7/7/95	Subtotal
Participant	Member _____	U$ 100	U$ 120	
	Student Member _____	U$ 60	U$ 65	
	Non-member _____	U$ 120	U$ 140 (inc. bal. yr. mbrs.)	
	Student Non-member _____	U$ 65	U$ 70 (inc. bal. yr. mbrs.)	

Housing and Meal Registration

	Quantity	Symposium Participant	Accompanying Person	Sub-total
Single Room w/meals	_____	$261/person	$261/person	_____
Single Room (no meals)	_____	Not Available	$180/person	_____
Addl. Single Rm./night (no meals)	_____	$45/person	$45/person	_____
Double Room w/ meals	_____	$225/person	$225/person	_____
Double Room (no meals)	_____	Not Available	$144/person	_____
Addl. Double Rm/night (no meals)	_____	$36/person	$36/person	_____
Family Apartment (with participant's meals only)	_____	$405/family	Included (no meals)	_____
Addl. Apt./night (no meals)	_____	$81/apt.	Included	_____

Name of Accompanying Person(s):

_____ _____ _____

Preferred Roommate (for those choosing a double room) _____

Arrival Date _____ Departure Date _____

For Accompanying Persons or Participants Staying Off Campus Only

	Quantity		Subtotal
Lunch Only Package	_____	US$40 (per person, Thursday through Sunday)	_____

Concluding BBQ Banquet Tickets for Guests Not Registered for the Symposium
(Symposium Participant's ticket included in registration)

Quantity	Before 8/26/95	On or After 8/26/95	Subtotal
_____	U$ 20	U$ 40	_____
		TOTAL	_____

****

Mailing Instructions **Receipt deadline: July 7, 1995**

Mail completed form and check for the total amount (payable to Society for Developmental Biology) to:
Annual Meeting registration, SDB, 9650 Rockville Pike, Bethesda, MD 20814-3998
Badges and Program/Abstract Book will be available at the Symposium. Please enclose a stamped, self-addressed postcard for acknowledgement of pre-registration receipt. We will not be able to verify pre-registration form receipt by phone.
Housing confirmation will be mailed to you from the UCSD housing office.

SOCIETY FOR DEVELOPMENTAL BIOLOGY
54TH. ANNUAL SYMPOSIUM

Welcoming Program Pre-meeting Announcement

Just a reminder to all of you planning to attend the meeting: don't forget about the Welcoming Program. If you're interested in showing a first-time meeting participant the ropes, or if you're a first-time attendee and are interested in being shown the ropes, be sure to fill up the following registration form and return to:

Dr. Bill Bement
Dept. of Zoology
Univ. of Wisconsin
1117 West Johnson St.
Madison, WI 53706

****

Welcoming Program Registration Form

Would you like to participate in the Welcoming Program? As described in the SDB newsletter (Winter '95 issue), this program matches first-time meeting attendees with more-experienced meeting goers for an hour or two at the start of the meeting. If you are interested in participating, check the appropriate space below.

NAME _____

Position _____

Address _____

Phone _____ e-mail _____

_____ I'm a first time SDB meeting attendee and I would like to participate in the Welcoming Program.

_____ I've been to SDB meetings before and I would like to participate in the Welcoming Program. I will / will not (circle one) be present at the beginning of the meeting.

Society for Developmental Biology 54th Annual Symposium



Genes, Development & Cancer

August 26-30, 1995
University of California San Diego

Organizers:
Helen Blau
Nadia Rosenthal

Local Organizer:
Victor Vacquier

David Anderson
Barbara Barres
Mina Bissell
Juan Botas
Marianne Bronner-Fraser
Margaret Buckingham
Hermann Bujard
Dave Capco
Kenneth Chien
Don Cleveland
Judith Croxdale
Eric Davidson
Jeffery Dangl
Eddy de Robertis
Robert Eisenman
Anne Ephrussi
Anne Fausto-Sterling
Mark Fishman
Kathleen Rae Foltz
Scott Fraser
Norton Gilula
Corey Goodman
Jon Graff
John Gurdon
Elizabeth Hay
William Jefferey
Alex Joyner
Michael Karin
Ed Laufer
Jeanne Lawrence
Cecilia Lo
Sharon Long
Daniel Louvard
Anthony Mahowald
Diana Myles
Lee Niswander
Gary Nolan
Roel Nusse
Bjorn Olsen
Eric Olson
Brad Olwin
Charles Ordahl
Patrick O'Farrell
Roger Pedersen
Janet Rossant
Gary Ruvkun
David Sassoon
Jerry Schatten
Matthew Scott
Lucy Shapiro
Carla Shatz
Charles Sherr
Robert Singer
Nahum Sonenberg
Claudio Stern
Jean Wang
Gerry Weinmaster
Marvin Wickins
Moshe Yaniv
Kai Zinn

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Nadia Rosenthal, Ph.D.
Associate Professor of Medicine
Cardiovascular Research Center
Massachusetts General Hospital-East
149 13th Street, Rm 4325
Charlestown, MA 02129

Re: #4260

Subject: Genes, Development and Cancer
Date: August 26-30, 1995
Location: University of California, San Diego

Dear Dr. Rosenthal:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The Society for Developmental Biology and forwarded to the Society, at 9650 Rockville Pike, Bethesda, MD, 20814-3998, together with a copy of this letter.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file

Auditors, ROK, LP, Administrative Actions

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

April 20, 1995

Nadia Rosenthal, Ph.D.
Associate Professor of Medicine
Cardiovascular Research Center
Massachusetts General Hospital-East
149 13th Street, Rm 4325
Charlestown, MA 02129

Re: #4260

Subject: Genes, Development and Cancer
Date: August 26-30, 1995
Location: University of California, San Diego

Dear Dr. Rosenthal:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The Society for Developmental Biology and forwarded to the Society, at 9650 Rockville Pike, Bethesda, MD, 20814-3998, together with a copy of this letter.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc: Dr. H. McAllister
file

Auditors, ROK, LP, Administrative Actions

95-17

MASSACHUSETTS GENERAL HOSPITAL ◆ HARVARD MEDICAL SCHOOL

CARDIOVASCULAR RESEARCH CENTER

Nadia Rosenthal, Ph.D.
Associate Professor i n Medicine
617/724-9560
617/724-9561 (fax)

Cardiovascular Research Center
Massachusetts General Hospital - East
149 13th Street, 4th floor
Charlestown, Massachusetts 02129
Tel. 617-726-7663
Fax: 617-726-5806

3/21/95
Will send manuscript and letter from SDB

February 8, 1995

Harmon C. McAllister, Ph.D.
Council for Tobacco Research-U.S.A., Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. McAllister:

We are writing to ask your support for the 1995 Annual Meeting of the Society for Developmental Biology on "Genes, Development and Cancer" to be held August 26 through August 30, 1995 at the University of California, San Diego.

This year's symposium is organized by Helen M. Blau, current President of the SDB, together with Nadia Rosenthal, Associate Professor at Harvard Medical School, and will be attended by researchers and teachers interested in the study of development, including graduate students and postdoctoral fellows. We expect that, as during the past 7 years, the meeting will be of medium size (300-400 registrants), and we encourage junior level attendance by providing them some financial support. The meeting will include a broad range of topics, following the extremely successful organization of talks and posters that was newly established for the past two years' SDB annual meetings. Plant, animal and microbial systems will all be represented in session organized around "themes" rather than specific systems or organisms. A particular focus will be the control of the cell cycle and its relationship to developmental processes and cancer. We plan 60 scientific talks, beginning with an opening evening keynote address. Highlighted during the next 3 days will be a series of 1 keynote and 6 plenary sessions that include 18 exciting invited speakers. Additionally, there will be 8 "minisymposia" arranged in 2 sessions (4 minisymposia running in parallel during each session). The minisymposia will be organized and chaired by experts in the areas and at least two talks will be given by junior people in each, thus providing them with an opportunity to speak at the national level. Poster sessions will also provide opportunities for young people to present their work. These will be available for viewing during most of the meeting providing ample time for discussion. Reflecting the growing role of the SDB in the affairs and concerns of its membership, this year's meeting will include three issue-oriented workshops on education, the concerns of women, and on the concerns of minorities.

It is clear that this will be a highly attended and important conference. We have requested funds from the National Institutes of Health to help defray travel costs for speakers and young scientists. However, the budgets of these agencies are, as you know, extremely tight and the support we anticipate receiving for this conference will be grossly inadequate. We are therefore depending on the generosity and long term vision of corporations to help insure the success of this conference. Speakers having limited grant support, especially junior faculty, may cancel their participation in the meeting unless we can provide funds to cover a significant portion of their essential travel/lodging expenses. Speakers do not receive lecture fees or honoraria.

Should you be able to make a contribution to this important meeting, it should be made payable to the Society for Developmental Biology, and sent to:

The Society for Developmental Biology,
9650 Rockville Pike, Bethesda, MD, 20814-3998
(tel) 301/571-0647, (fax) 301/530-7049

If written notice of intent is received promptly, your contribution will be acknowledged in symposium announcements as well as at the meeting. Please contact Dr. Ida Chow at the address below if you have any questions concerning corporate/foundation support to the Society for Developmental Biology. We would be happy to provide further information regarding the scientific content of this conference.

Sincerely,

Helen Blau, Ph.D.
President
Society for Developmental Biology
9650 Rockville Pike
Bethesda, MD 208140-3998

Nadia Rosenthal, Ph.D.
Associate Professor in Medicine
Cardiovascular Research Center
Massachusetts General Hospital-East
149 13th Street, Room 4325
Charlestown, MA 02129

Dr. Ida Chow
Department of Biology
The American University
4400 Massachusetts Ave., NW
Washington, D.C.
20016-8007

MASSACHUSETTS GENERAL HOSPITAL ◆ HARVARD MEDICAL SCHOOL

CARDIOVASCULAR RESEARCH CENTER

Nadia Rosenthal, Ph.D.
ssociate Professor of Medicine
617/724-9560
617/724-9561 (fax)

Cardiovascular Research Center
Massachusetts General Hospital - East
149 13th Street, 4th floor
Charlestown, Massachusetts 02129
Tel. 617-726-7663
Fax: 617-726-5806

March 24, 1995

Dr. George Hashim
Council for Tobacco Research - U.S.A.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

Per your recent request, attached is a listing of speakers for the 54th Annual Symposium for the Society for Developmental Biology. Thank you very much for considering our application for support for the upcoming SDB meeting. Please don't hesitate to contact us if there is anything else we can do to assist your evaluation of said application.

Sincerely,

Nadia Rosenthal

Nadia Rosenthal, Ph.D.
Associate Professor of Medicine
mb

attch

Society for Developmental Biology
54th Annual Symposium

University of California, San Diego
August 26-30, 1995
Abstract Deadline: April 14, 1995

Genes, Development, and Cancer

Co-Organizers: Helen Blau (President, SDB) and
Nadia Rosenthal

The meeting is typically of medium size, so that all meals are covered by the registration fee and enjoyed together to foster interactions among researchers and teachers interested in the study of development. The meeting will include a broad range of topics. Reflecting the growing role of the SDB in the affairs and concerns of its membership, this year's meeting will include several issue-oriented workshops and special luncheons on education, ethics, and the concerns of the diversity of scientists: women, gays, and minorities. We make every effort to keep costs low in order to encourage junior level attendance. Moreover, last year each minisymposium had at least one speaker selected from submitted abstracts, and two poster winners received travel awards to England and to Chile, respectively.

Saturday
8:00 PM Keynote Address: Carla Shatz
9:00 PM Poster session and Social

Sunday
8:30-11:30 AM **Plenary Session I – Genetic analysis of cell lineage**
Eric Olson (chair), Anthony Mahowald, David Anderson, Alex Joyner
Special Lunch (optional) - Minorities Interests
1:30-3:00 PM Poster session
3:00-5:00 PM **Minisymposia**
1) Inductive mechanisms in development
Elizabeth Hay (chair), Claudio Stern, Anne Ephrussi, Juan Botas, Jon Graff
2) Limb development
Margaret Buckingham (chair), Brad Olwin, Lee Niswander, Ed Laufer
3) Nervous system development
Marianne Bronner-Fraser (chair), Corey Goodman, Kai Zinn, Barbara Barres
4) Membrane, cytoskeleton, and cell signalling
Daniel Louvard (chair), Don Cleveland, Michael Karin, Garry Nolan
Dinner
7:00-9:15 PM **Plenary Session II – Polarity and patterning**
Matthew Scott (chair), Janet Rossant, Eddy de Robertis
9:30 PM Mixer at Posters

Monday
8:30-11:30 AM **Plenary Session III – Post-transcriptional control of gene expression**
Marvin Wickens (chair), Helen Blau, Robert Singer, Gary Ruvkun
Special Lunch (optional) - Ethical Issues (organized by Jerry Schaffer)
1:30-3:00 PM Poster session
3:00-5:00 PM **Minisymposia**
1) Cell-cell interactions
Norton Gilula (chair), Scott Fraser, Gerry Weinmaster
2) Organogenesis
Mark Fishman (chair), Kenneth Chien, Jeffery Dangl, David Sassoon
3) Fertilization/activation of development
Victor Vacquier (chair), William Jeffery, Diana Myles, Kathleen Foltz
4) Molecules and morphogenesis
Merton Bernfield (chair), Charles Ordahl, Bjorn Olsen
Dinner
7:00-10:00 PM **Plenary Session IV – Transcriptional control in differentiation and cancer**
Robert Eisenman (chair), Nadia Rosenthal, Moshe Yaniv, Hermann Bujard
8:30-10:30 PM Mixer at Posters

Tuesday
8:30-10:00 AM Workshops - Educational issues (organized by David Capco)
10:30-12:45 PM **Plenary Session V – Cell communication in development and cancer**
John Gurdon (chair), Mina Bissell, Roel Nusse
Special Lunch - Diversity Issues (organized by Judith Croxdale)
1:30-3:45 PM **Plenary Session VI – Cell cycle control in development and cancer**
Patrick O'Farrell (chair), Nahum Sonenberg, Charles Sherr
4:00 PM Best posters presentation
SDB Business meeting
Concluding banquet
Speaker: Eric Davidson "A historical perspective"

Wednesday
8:30-10:00 AM **Plenary Session VI – Cell compartmentalization in development**
Lucy Shapiro (chair), Jeanne Lawrence, Jean Wang
Lunch

The abstract submission deadline is **April 14, 1995**, and pre-registration deadline for the meeting and housing is **July 7, 1995**.
For more information, contact Society for Developmental Biology, 9650 Rockville Pike, Bethesda, MD 20814
Tel: 301-530-0647; Fax: 301-530-7049

#4115-New Developments on the Funct. of Myelin Assoc. Glycopro.
93/5-9, 1995 Santa Monica, CA

2101
8/29/94



American Society for Neurochemistry, Inc.

Lynn Wecker, Ph.D.
Treasurer

12 September 1994

Dr. George A. Hashim
The Council for Tobacco Research-U.S.A., Inc.
900 Third Avenue
New York, New York 10022

Dear Dr. Hashim:

On behalf of the American Society for Neurochemistry, Inc., I would like to thank you for your donation of $500 to support a symposium on "Myelin-Associated Glycoprotein" organized by Dr. Marie Filbin to be held at our Annual Meeting in Santa Monica, California, March 5-9, 1995. This donation will enable Dr. Filbin to invite speakers who are outstanding leaders in the field, contributing significantly to the quality of our scientific program.

Again, thank you very much for your kind donation. We sincerely appreciate your contribution and will acknowledge such in our meeting program, which will be sent to you when it becomes available in the spring, 1995.

Sincerely,

Lynn Wecker, Ph.D., Treasurer
American Society for Neurochemistry

cc: Dr. Marie T. Filbin
Department of Biological Sciences
Hunter College of the City of New York
695 Park Avenue
New York, New York 10021

Chair, Dept. of Pharmacology and Therapeutics, University of South Florida College of Medicine
12901 Bruce B. Downs Blvd., MDC Box 9, Tampa, Florida 33612 Phone: 813-974-2543 Fax: 813-974-3081

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Marie T. Filbin, Ph.D.
Department of Biological Sciences
Hunter College of the City of New York
695 Park Avenue
New York, N.Y. 10021

Re: 4115

Subject: New Developments on the Functioning of Myelin Associated Glycoprotein.
Date: March 5-9, 1995
Location: Santa Monica, CA

Dear Dr.Filbin:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $500 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The American Society for Neurochemistry, was forwarded(with a copy of this letter) to the ASN Treasurer, Professor Lynn Wecker.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Bcc: AUDITORS, ROK, LP
ADMINISTRATIVE ACTIONS

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Marie T. Filbin, Ph.D.
Department of Biological Sciences
Hunter College of the City of New York
695 Park Avenue
New York, N.Y. 10021

Re: 4115

Subject: New Developments on the Functioning of Myelin Associated Glycoprotein.
Date: March 5-9, 1995
Location: Santa Monica, CA

Dear Dr.Filbin:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $500 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The American Society for Neurochemistry, was forwarded(with a copy of this letter) to the ASN Treasurer, Professor Lynn Wecker.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Bcc: AUDITORS, ROK, LP
ADMINISTRATIVE ACTIONS

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Department of Biological Sciences
(212) 772-[redacted]
5270

HUNTER
HUNTER COLLEGE
OF THE CITY UNIVERSITY OF NEW YORK

$500 94-26 $5-5

Dr. George Hashim,
Ass. Res. Director,
The Council for Tobacco Research,
900 3rd Ave.,
New York, NY 10022

18th May '94

March 9, 1995

Dear Dr. Hashim,

I am organizing a colloquium at the 1995 meeting of the American Society for Neurochemistry, to be held in Santa Monica, California. The title of the colloquium is "**New Developments on the Functioning of Myelin Associated Glycoprotein (MAG).**" The speakers and the topics are as follows:

Dr. John Roder (Toronto, Canada) --- Behavioral, morphological and biochemical characterization of MAG knockout mice.

Dr. Paul Crocker (Oxford, England) --- Binding characteristics and identification of the MAG receptor.

Dr. Tadashi Yamamoto (Tokyo, Japan) --- The interaction of MAG with Fyn and signal transduction.

Dr. Marie T. Filbin (New York, USA) --- The ability of MAG to inhibit or to promote neurite outgrowth.

Recently, as can be seen from the titles of the talks, there have been many new and exciting advances in elucidating the functioning of MAG. In particular, the novel observation that MAG is a potent inhibitor of neurite outgrowth may have important therapeutic value in the long-term with respect to defining conditions that would permit nerve regeneration after injury. In addition, the role of MAG in myelination has also progressed tremendously; how MAG signals and identification of the MAG receptor will soon be revealed.

To bring together scientists at the forefront of this research meant bringing together people from four different countries; England, Canada, Japan and USA. The expenses of the speakers are not covered by the American Society for Neurochemistry, so I must raise the funds from other sources otherwise the colloquium will not take place. As your research foundation is interested in supporting basic research I am therefore asking for a contribution towards the travel/accommodation of the speakers. I am trying to raise $3,500. If you can provide some support, an acknowledgment will be printed in the program.

I look forward to hearing from you.

Yours sincerely,

Marie T. Filbin

Marie T. Filbin Ph.D.
Associate Professor
Phone 212 772 5270
FAX 212 772 5227

#4116-Ninth Int'l. Symp. on Calc~~i~~u
/29-5/3/95, Airlie Center, VA

3716
8/29/94

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Anthony R. Means, Ph.D.
Department of Pharmacology
Duke University Medical Center
Box 3813
Durham, NC 27710

Re: 4116

Subject: Ninth International Symposium on Calcium and Calcium Binding Proteins in Health and Disease.
Date: April 29-May 3, 1995
Location: Airlie Center, VA

Dear Dr.Means:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The Ninth International Symposium on Calcium, is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: AUDITORS, ROK, LP,
ADMINISTRATIVE ACTIONS

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Anthony R. Means, Ph.D.
Department of Pharmacology
Duke University Medical Center
Box 3813
Durham, NC 27710

Re: 4116

Subject: Ninth International Symposium on Calcium and Calcium Binding Proteins in Health and Disease.
Date: April 29-May 3, 1995
Location: Airlie Center, VA

Dear Dr.Means:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The Ninth International Symposium on Calcium, is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: AUDITORS, ROK, LP,
ADMINISTRATIVE ACTIONS

(94-33) 44-285

Ninth International Symposium on Calcium-Binding Proteins and Calcium Function in Health and Disease

April 29 - May 3, 1995 The Airlie Center, Airlie, VA, U.S.A.

July 20, 1994

JK

Department of Pharmacology
Duke University Medical Center
Box 3813
Durham, NC 27710
Tel. (919) 681-6209
Fax. (919) 681-7767

Harmon C. McAllister
Research Director
The Council for Tobacco Research-U.S.A., Inc.
900 Third Avenue
New York, NY 10022

Dear Mr. McAllister:

I am responsible for organizing the Ninth International Symposium on Calcium and Calcium Binding Proteins in Health and Disease. This meeting will be held 29 April - 3 May, 1995 at the Airlie Center in Airlie, Virginia, which is only about an hour from Washington. A list of the Organizing Committee membership and a one page purpose statement are enclosed as is a preliminary program.

As you will learn from perusal of the enclosures this meeting, which is only held every three years, has become the primary meeting on calcium and the only one to focus on calcium in human physiology and disease. Many of the topics to be covered are of particular interest to your organization. I am pleased to invite you to become a corporate sponsor of this important international meeting and urge you to consider a $5,000 contribution. We will acknowledge your gift in the Final Announcement, the Program and the Abstract booklet. Should it be your desire, we are happy to have you sponsor specific named lectures or a plenary session. In addition we are happy to have your designee attend the meeting.

Thank you for your consideration in this matter. Your contribution is vital to the success of the Airlie meeting. I will be happy to provide any additional information you might require.

With best wishes.

Sincerely yours,

ARMeans

Anthony R. Means, Ph.D.

ARM/lf

Committee(s) Members

Dr. John Gergely
Dept. of Muscle Res.
Boston Biomed. Res. Inst.
20 Staniford St.
Boston, MA 02114 USA

Dr. Robert H. Kretsinger
University of Virginia
Dept. of Biology
Gilmer Hall 924-7039
Charlottesville, VA 22904 USA

Dr. David H. MacLennan
Banting & Best
Dept. of Medical Research
Charles H. Best Institute
University of Toronto
112 College Street
Toronto ONT M5G 1L6
CANADA

Dr. Thomas C. Vanaman
Professor
Department of Biochemistry
University of Kentucky Medical Center
209 Combs Bldg.
Lexington, KY 40536-0096

Robert H. Wasserman, Ph.D.
James Law Professor
Department of Physiology
Cornell University
New York State College
Vet. Med. Res. Tower, Rm. 717
Ithaca, NY 14853-0001

Dr. R. J. P. Williams
University of Oxford
Inorganic Chemistry Lab.
South Parks Road
Oxford OX1 3QR
ENGLAND

Professor Ernesto Carafoli
Laboratory for Biochemistry
Swiss Federal Institute of Technology ETH
8092 Zurich, Switzerland

Dr. Hiroyoshi Hidaka
Dept. of Pharmacology
Nagoya University School of Medicine
Tsurumai-cho 65, Showa-ku
Nagoya 466 JAPAN

Sture Forsen, Ph.D.
Physical Chemistry 2
Chemical Centre
P. O. Box 12Y 5-2210
Lund, Sweden

Dr. N. Michael Green
National Institute for Medical Research
The Ridgeway
Mill Hill, London NW 7 1AA
ENGLAND

Prof. Cyril Kay
3-31A Medical Sciences Bldg.
Dept. of Biochemistry
Univ. of Alberta
Edmonton, Alberta T6G 2H7
CANADA

Claude B. Klee, M.D.
Chief, Lab. of Biochemistry
NCI, NIH
Bldg. 37, Rm 4E28
Bethesda, MD 20892-0001

Anthony R. Means, Ph.D.
Professor and Chairman
Department of Pharmacology
Duke University Medical Center
Box 3813
Durham, NC 27710

Dr. Anthony W. Norman
University of California
Division of Biomedical Sciences
Riverside, California 92521-.0121

James W. Putney, Ph.D.
Chief, LCMP
NIEHS, NIH
P. O. Box 12233
Research Triangle Park, NC 27709-2233

Dr. Brian D. Sykes
University of Alberta
Dept. of Biochemsitry
474 Medical Sciences Bldg.
Edmonton, Alberta T6G 2H7
CANADA

Trisha N. Davis, Ph.D.
Assistant Professor
Department of Biochemistry
University of Washington, SJ-70
Seattle, WA 98195-0001

Marcel Dorée
Cell Biology
CRBM, CNRS-INSERM
BP 5051, 1919 Route de Mende
34033 Montpellier Cedex
FRANCE

Dr. Barbara Seaton
Dept. of Physiology
Boston Univ. Schl. of Med.
80 E. Concord St.
Boston, MA 02118

Dr. Franklyn Prendergast
Mayo Clinic/Foundation
200 First St., SW
Rochester, MN 55905

Ninth International Symposium on Calcium-Binding Proteins and Calcium Function in Health and Disease

April 29 - May 3, 1995 The Airlie Center, Airlie, VA, U.S.A.

Symposium Secretary

Department of Pharmacology
Duke University Medical Center
Box 3813
Durham, NC 27710
Tel. (919) 681-6209
Fax. (919) 681-7767

The Ninth International Symposium on Calcium and Calcium Binding Proteins in Health and Disease will be held at the Airlie House in Airlie, Virginia from 29 April to 3 May, 1995. The first meeting in this series took place in Poland in 1974. Originally the organizers intended to bring together scientists from diverse fields that were interested in calcium. The success of the first meeting prompted assembly of an official Organizing Committee that, with deletions and additions, has overseen all subsequent meetings. This series is the only one that deals with all aspects of calcium and makes an effort to cover exciting new advances regardless of the particular discipline involved. It is apparent that the field has literally exploded in the 20 years that have passed since the original meeting in Poland.

Calcium is now appreciated as one of the most important intracellular second messengers being crucial for secretion, motility, intermidary metabolism and cell division. In addition the calcium concentration in the extracellular fluid is tightly controlled by three hormones. Extracellular calcium participates in cell adhesion, organogenesis and serves as a ligand for a newly discovered transmembrane receptor. Thus defects in calcium homeostasis either intracellularly or extracellularly can lead to a variety of human diseases from rickets to malignant hyperthermia. To capitalize on the remarkable diversity of this divalent cation, we will focus the 1995 meeting on four broad but interrelated topics. These topics are: 1) Physiological Roles for Calcium; 2) Calcium Homeostasis; 3) Structural Bases for Calcium Regulation; and 4) Calcium Mediated Pathways in Human Disease. The Organizing Committee will assemble 10 sessions each of which will feature 4 speakers. Each session will have a Discussion Leader from among the members of the Organizing Committees who has made seminal contributions in the specific topic to be presented. We have presently secured 34 of these speakers the list of which includes 8 women, 2 minority, 9 young scientists and 12 participants from countries other than the USA. We plan to delay filling the final 6 slots to accommodate late breaking exciting advances in any or all of the four broad topics. In addition to the platform sessions, we will feature evening poster sessions. The Committee will select several of these poster abstracts for round table type short oral presentations. In this way we can involve virtually all participants in the funtional aspects of the meetings. We feel that the timing of this meeting is excellent and it will be the most successful yet of the meetings devoted to calcium.

Preliminary Program

A. Physiological Roles for Calcium

1.	Leslie Griffith: USA	Calmodulin kinase and neuronal plasticity in *Drosophila*
2.	Howard Schulman: USA	Nuclear translocation of calmodulin kinase in cardiomyocytes
3.	Patrick McDonough: USA	Electrical pacing of ventricular myocytes causes hypertrophy via a calcium/calmodulin dependent pathway
4.	Kyle Cunningham: USA	Calcium entry pathways in yeast define a functional role for calcineurin
5.	Yoshi Ohya: Japan	Essential roles for calmodulin in yeast
6.	Stephen Bolsover: USA	Nuclear calcium transients
7.	Robert Hinrichsen: USA	Calmodulin mutants in Paramecium define cation pumps required for ciliary motility
8.	Martha Cyert: USA	The role of calcineurin in mating factor-induced cell cycle arrest
9.	Kathy Beckingham: USA	Calcium mediated pathways in *Drosophila*
10.	David Levin: USA	PKC mediated pathways in yeast

B. Calcium Homeostasis

1.	Ernesto Carafoli: Switzerland	Molecular characterization of the plasma membrane calcium pumping ATPase
2.	Katsuhiro Mikoshiba: Japan	Molecular Characteristics of the inositol trisphosphate receptor
3.	Ludwig Missiaens: Belgium	Molecular characterization of the ryanodine receptor
4.	Barbara Erlich: USA	Single channel characteristics of the IP_3 and ryanodine receptors
5.	Michael Berridge : UK	The second messenger characteristics of IP_3

B. Calcium Homeostasis (continued)

6.	Roger Tsien: USA	Molecular nature of the signal that regulates the capacitive calcium entry pathway
7.	Lutz Birnbaumer: USA	Identification and molecular characteristics of the capacitive calcium entry channel
8.	Robert Malenka: USA	Molecular regulation of LTP and LTD by calcium dependent enzymes

C. Structural Bases for Calcium Regulation

1.	Louise Johnson: UK	Crystal structure of the catalytic subunit of phosphorylase kinase
2.	Barbara Seaton: USA	The 3 dimensional structure of annexin V
3.	Franklyn Prendergast: USA	Calmodulin interaction with D-amino acid amphiphilic peptides
4.	Bill Cook: USA	3D structure of Ca^{2+}/calmodulin complexed to an antagonist
5.	Maria Sunnerhagen: Sweden	Structural basis for Ca^{2+} binding to Factor X
6.	Carolyn Cohen: USA	Structure of myosin light chains associated with myosin
7.	Brian Sykes: USA	Apo and Ca^{2+} bound structures of the NH_2-terminal domain of Troponin C
8.	Bruce Kemp: Australia	Structural basis for Ca^{2+} regulated autoinhibition of enzymes

D. Calcium Mediated Pathways and Human Disease

1.	David MacLennan: Canada	The molecular basis for malignant hyperthermia
2.	Edward M. Brown: USA and	The calcium sensing receptor and mutations that result in hypocalciuric hypercalcemia neonatal hyperparathyroidism
3.	Stuart Schreiber: USA	Mechanism of action of immunosuppressive drugs

D. Calcium Mediated Pathways and Human Disease (continued)

4.	S. Orrenius: Sweden	Calcium mediated apoptosis
5.	David Brendt: USA	Nitric oxide synthase deficient mice
6.	Donald McDonnell: USA	Hormonal antagonists of osteoporosis
7.	Gregory R. Mundy: USA	The molecular basis for malignancy-associated hypercalcemia
8.	Hiroshi Hidaka: Japan	Inhibitors of calmodulin dependent enzymes

#4117-THE 1995 DEUEL CONF. ON LIPIDS, Monterey, CA, 3/7-10/95

3-7014
8/29/94

THE 1995 DEUEL CONFERENCE ON LIPIDS

March 20, 1995

Dr. Harmon McAllister
The Council for Tobacco Research - U.S.A., Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. McAllister:

I am writing to thank you again for having contributed to and participated in the 1995 Deuel Conference. I am sure you will agree that the meeting was a success and the quality of the science was extremely high. I have received many positive comments about the overall program from many of the participants. Your contribution was vital in enabling us to invite the caliber of speaker that we did. I sincerely hope that you will continue to support this exciting and important conference in the future and again would like to acknowledge my appreciation of your help.

Sincerely,

Alan Chait, M.D.
Professor of Medicine
Chair, Program Committee

em
cc: George A. Hashim, Ph.D.

THE 1995 DEUEL CONFERENCE ON LIPIDS

File

January, 1995

George A. Hashim, Ph.D.
Associate Research Director
The Council for Tobacco Research - USA, Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

Thank you for your contribution to the 1995 Deuel Conference on Lipids, which will be held March 7-10 at the Monterey Plaza Hotel in Monterey, California.

Registration material for the conference is enclosed. In accord with Conference policy, room and board (at the twin (share) double-occupancy, per-person rate of $460.00) of sponsors will be paid by the Deuel Conference. You may request single room accommodations and pay the single room supplement of $280.00. Parking is included in the Conference package. You will be responsible for any incidental charges incurred at time of check out. Check-in time is 5:00 p.m.on Tuesday, March 7 and check-out time is 12:00 p.m. on Friday, March 10. The Conference will commence on Tuesday evening, March 7 at 6:30 p.m. with a wine tasting reception and dinner.

Travel time from the San Francisco International airport is approximately two hours. The Monterey Peninsula Airport is a ten minute taxi ride from the hotel and is serviced by American, United, US Air and Delta Airlines. Complete transportation information is enclosed.

It is essential that the hotel accommodations form be returned together with payment in full of fees, if applicable, to Dr. Richard Havel before **January 24**.
An envelope is provided for your convenience.

We have had an excellent response to the program and look forward to a stimulating and productive meeting. A copy of the tentative program is enclosed. As in the past, the Deuel Conference maintains an informal atmosphere. Material presented at the conference will not be recorded or published in order to encourage free discussion. All conferees are expected to be present for the entire meeting.

We look forward to seeing you at the Monterey Plaza Hotel.

Sincerely,

Alan Chait
1995 Program Chairman

Enclosures

THE 1995 DEUEL CONFERENCE ON LIPIDS

October 12, 1994

George A. Hashim, Ph.D.
Asociate Research Director
The Council for Tobacco Research - U.S.A., Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

I want to thank The Council for Tobacco Research for your contribution in the amount of $2,000 in support of the 1995 Deuel Conference on Lipids which will be held in Monterey, California. We appreciate the continued support of The Council for Tobacco Research and look forward to meeting with you or your representative at the conference in March of 1995.

As indicated below, I have copied this letter to Drs. Havel, Chait and Fielding. Drs. Havel and Chait will send information regarding details of the conference to you or your representative, including registration information and final schedule of the meetings.

Please let them know if someone other than yourself will attend the meetings.

Thank you for your generous and continued support.

Sincerely,

Edwin L. Bierman, M.D.
Professor of Medicine
Funding Chair, 1995 Deuel Conference

em
c: Dr. Havel
Dr. Fielding
Dr. Chait

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Dr. Edwin L. Bierman
Department of Medicine
Division of Metabolism, RG-26
University of Washington
Seattle, WA 98195

Subject: The 1995 Deuel Conference on Lipids Re: 4117
Date: March 7-10, 1995
Location: Monterey, CA

Dear Dr. Bierman:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $2,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The 1995 Deuel Conference on Lipid is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: Auditors, ROK, LP
Administrative Actions

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Dr. Edwin L. Bierman
Department of Medicine
Division of Metabolism, RG-26
University of Washington
Seattle, WA 98195

Subject: The 1995 Deuel Conference on Lipids
Date: March 7-10, 1995
Location: Monterey, CA

Re: 4117

Dear Dr. Bierman:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $2,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to The 1995 Deuel Conference on Lipid is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: Auditors, ROK, LP
Administrative Actions

THE 1995 DEUEL CONFERENCE ON LIPIDS

1 August 1994

George A. Hashim, Ph.D.
Associate Research Director
Council for Tobacco Research - USA, Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

The 1995 Deuel Conference on Lipids has been set for March 7-10, 1995 in Monterey, California.

The program is being organized by Dr. Alan Chait of the University of Washington with the following tentative proposed topics:

1. *Lipases and esterases*

Mutations in lipoprotein lipase: hormone sensitive lipase in macrophages; platelet activating factor acetyl hydrolase and paraoxonase

2. *Oxidative processes in atherosclerosis*

Cellular mechanisms of LDL oxidation; antioxidants - structure and function; gene regulation by reactive oxygen species and oxidized lipids

3. *Proteoglycan-lipoprotein interactions*

Proteoglycans in the extracellular matrix of the artery wall; glycosaminoglycans-lipoprotein lipase interaction; role of cell surface glycosaminoglycans in lipoprotein receptor interactions

4. *New animal models for the study of atherosclerosis*

Cholesterol ester transfer protein transgenic mice; transgenic rabbits; homologous recombination to achieve cytokine deficiency; use of animal models for arterial wall imaging.

5. *Nutrition*

Vitamin E and disease states; transfatty acids and atherosclerosis; nutrients in gene regulation; genetics of dietary responsiveness

6. *HDL*

Rare HDL apolipoproteins; HDL binding proteins; HDL species involved in cholesterol efflux

I have enclosed a copy of last year's program so that you can get an idea of the scope of the program.

The Deuel Conference maintains an informal atmosphere, encourages free and open discussions by all attendees, and is a forum for presentation of new and unpublished data in rapidly developing new fields of research. A copy of brief background information on the Deuel Conference and a copy of last year's program are enclosed for your information.

The Deuel Conference is supported by donations from companies with an interest in lipid research, such as your own, and we are therefore soliciting your financial support. Because of the limitations on the conference size, it is necessary to restrict supporting organizations to two representatives at the round table at a minimum donation of $2,000 per representative and we are soliciting primarily those who have supported us in the past, or those who have expressed an interest in supporting this conference. We hope that you are interested in sending a representative to the conference. If this is indeed the case, we would be delighted. Please contact me as soon as possible with the name and address of the attendee as well as your contribution to the Deuel Conference and I will forward that information to Dr. Havel's office and to Dr. Chait's office. In order for us to plan accordingly, an immediate reply is most desirable, with definite commitment by November 1, 1994 at the very latest.

We hope to hear from you in the near future and to see you or your representative next March.

Sincerely,

Edwin L. Bierman, M.D.
Funding Chairman

em
enc. (program for 1994 and history)

THE 1995 DEUEL CONFERENCE ON LIPIDS

Background Information on the Deuel Conference on Lipids

The Deuel Conference on Lipids was organized by a small group of eminent West Coast scientists interested in lipid research, to provide a conference on lipids for western states similar to the Gordon Conference held in the east. Shortly after it was organized, one of the founders, Harry Deuel, died and the conference was named in his memory. The conference has been held annually since about 1955 in various West Coast locations.

Generally the conference is devoted to one or two subjects and both basic and clinical materials are presented. The two and one-half day conference consists of five sessions beginning Wednesday or Thursday morning and running until Friday or Saturday, and is held in late February or early March. Each session is introduced by a speaker chosen for his or her high stature in the field. These speakers review their own and related work. Each review is followed by a few small presentations and general discussion of a disease process. Informality and wide interchange of information and views are encouraged by limiting the size of the groups, by the round table format, and by not recording or publishing the discussions.

Until 1968, the conferences were organized by Dr. L.W. Kinsell; since that time they have continued under broadly based rotating leadership. The original policies of the conference have been preserved to keep within the traditional budget, to maintain the informal atmosphere, and to provide the depth and breadth of expertise necessary for a high quality conference.

The attendance has been kept at less than 100 persons to insure informality. A few established investigators in the field of lipids, mostly from west of the Continental Divide, are regularly invited to attend. Lipid scientists in the west are informed of the coming program and are invited to apply for a place around the table. The Program Chairperson selects participants on the basis of relationship of the research interests of applicants to the program. These participants provide their own travel and living expenses, and all attendees are expected to be present for the entire conference.

The funds to defray the expense of speakers and conference costs are sought from industrial firms which have a general interest in the area of lipids. Donors are extended the privilege of sending a participant to the conference. However, because of the limited size and increasing interest in the conference, it has become necessary recently to adopt the policy of restricting the participants of the supporting firms to two, with a minimum donation of $2,000 per attendee.

E. L. Bierman, Chairman
Funding Committee
1995 Deuel Conference on Lipids

THE 1995 DEUEL CONFERENCE ON LIPIDS

4 August 1994

To whom it may concern:

Several days ago I mailed a letter to you regarding the 1995 Deuel Conference on Lipids. While I remembered to update the letter as to program, date, and committee members, I left the location as it had been for 1994. Please replace the first page of the request with the enclosed first page. The Deuel Conference will be in Monterey, California this year.

Sincerely,

Ellen Meyer

Ellen Meyer
for Edwin L. Bierman, M.D.
Funding Chairman

PARTICIPANTS AND INVITED GUESTS

Matthew Ashby, University of California, Berkeley
Alan Attie, University of Wisconsin, Madison
Salman Azhar, Veterans Administration Medical Center, Palo Alto
Carole L. Banka, The Scripps Research Institute, La Jolla
Hugh Barrett, University of Washington, Seattle
William F. Beltz, University of California, San Diego
Thomas P. Bersot, Gladstone Foundation Laboratories, San Francisco
Jeffrey T. Billheimer, DuPont Merck Pharmaceutical Company, Wilmington, DE
Clifton Bogardus, National Institutes of Health, Phoenix
William A. Boisvert, The Scripps Research Institute, La Jolla
Michael R. Briggs, Ligand Pharmaceuticals, San Diego
John D. Brunzell, University of Washington, Seattle
Alan Chait, University of Washington, Seattle
Yu-Sheng Chao, Merck Research Laboratories, Rahway, NJ
Israel Charo, Gladstone Foundation Laboratories, San Francisco
C. Chatzidakis, Procter and Gamble Company, Cincinnati
Y-D Ida Chen, Stanford University Medical Center
Marian C. Cheung, University of Washington, Seattle
William E. Connor, Oregon Health Sciences University, Portland
Allen D. Cooper, Palo Alto Medical Foundation
Eliana Cotta de Faria, Palo Alto Medical Foundation
Linda K. Curtiss, The Scripps Research Institute, La Jolla
Richard C. Davis, University of California, Los Angeles
Roger A. Davis, San Diego State University
Samir S. Deeb, University of Washington, Seattle
Douglas B. DiRienzo, National Dairy Council, Rosemont
P. Barton Duell, Oregon Health Sciences University, Portland
Cheryl A. Dyer, The Scripps Research Institute, La Jolla
Peter Edwards, University of California, Los Angeles
John Elovson, University of California, Los Angeles
Sandra K. Erickson, University of California, San Francisco
Robert Farese, Gladstone Foundation Laboratories, San Francisco
Kenneth Feingold, University of California, San Francisco
Maria Luz Fernandez, University of Arizona, Tucson
Trudy M. Forte, Lawrence Berkeley Laboratory
David M. Foster, University of Washington, Seattle
Philip Frost, University of California, San Francisco
Christopher Glass, University of California, San Diego
Richard Gregg, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ
Robert L. Hamilton, University of California, San Francisco
Randolph Hampton, University of California, Berkeley
Richard J. Havel, University of California, San Francisco
[illegible] Herscovitz, Boston University
Joachim Herz, University of Texas Southwestern Medical Center, Dallas
Jan L. Hoover-Plow, The Scripps Research Institute, La Jolla
Richard L. Jackson, Wyeth-Ayerst Research, Mammouth Junction, NJ
Talwinder S. Kahlon, USDA Western Regional Research Center, Albany, CA
John P. Kane, University of California, San Francisco
Fred Kern, Jr., University of Colorado, Denver
Philip Kern, Cedars Sinai Medical Center/UCLA
Michael Komaromy, Palo Alto Medical Foundation
Fredric B. Kraemer, Stanford University Medical Center
Ronald M. Krauss, University of California, Berkeley
Skaidrite Krisans, San Diego State University
Linda K. Kwong, University of Utah, Salt Lake City
Renée LeBoeuf, University of Washington, Seattle
Aldons J. Lusis, University of California, Los Angeles
Hanh L. Ly, University of California, San Francisco
Mary J. Malloy, University of California, San Francisco
Yves L. Marcel, Lipoproteins & Atherosclerosis Group, Ottawa
Carol A. Marzetta, Pfizer Central Research, Groton
Mara Massimi, Veterans Administration Medical Center, San Francisco
Harmon McAllister, Council for Tobacco Research-USA, Inc., New York
Sally McCormick, Gladstone Foundation Laboratories, San Francisco
David N. Nevin, University of Washington, Seattle
Roger S. Newton, Parke-Davis Pharmaceutical Research, Ann Arbor
Timothy Osborne, University of California, Irvine
Clive Pullinger, University of California, San Francisco
Adrian Recinos III, University of California, Berkeley
Karen Reue, Veterans Administration, Wadsworth, Los Angeles
Jerome Rotter, Cedars Sinai Medical Center/UCLA
Michael C. Schotz, University of California, Los Angeles
David Shames, University of California, San Francisco
Ishaiahu Shechter, Eleanor Roosevelt Institute, Denver
Franz R. Simon, University of Colorado, Denver
Michael Sinensky, Eleanor Roosevelt Institute, Denver
Jörg Spangenberg, The Scripps Research Institute, La Jolla
Arthur A. Spector, University of Iowa, Iowa City
Olga Stein, Rockefeller University, New York
Yechezkiel Stein, Rockefeller University, New York
Robert Superko, Lawrence Berkeley Laboratory
John Taylor, Gladstone Foundation Laboratories, San Francisco
John Trawick, San Diego State University
Dennis Vance, University of Alberta, Edmonton
Jean Vance, University of Alberta, Edmonton
Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas
Karl Weisgraber, Gladstone Foundation Laboratories, San Francisco
John Wetterau, Bristol-Myers Squibb, Princeton, NJ
Ladonna Wood, University of California, San Francisco
Stephen G. Young, Gladstone Foundation Laboratories, San Francisco
Xiaodong Zhu, University of Washington, Seattle

Last year's Program

THE 1994 DEUEL CONFERENCE ON LIPIDS

MARCH 8 TO 11

SILVERADO COUNTRY CLUB
NAPA, CALIFORNIA

PROGRAM COMMITTEE
ROGER A. DAVIS, CHAIR
ALAN CHAIT ALDONS J. LUSIS

ADVISORY BOARD
ARTHUR A. SPECTOR, CHAIR
ROBERT W. MAHLEY TRUDY M. FORTE
JOHN D. BRUNZELL LINDA K. CURTISS
RICHARD JACKSON

ARRANGEMENTS CHAIRMAN
RICHARD J. HAVEL

FINANCE CHAIRMAN
EDWIN L. BIERMAN

TREASURER
PHOEBE E. FIELDING

This conference is made possible through the generosity and vision of the following sponsors:

BRISTOL-MYERS SQUIBB PHARAMCEUTICAL RESEARCH INSTITUTE
THE COUNCIL FOR TOBACCO RESEARCH U.S.A. INC.
THE DUPONT MERCK PHARMACEUTICAL COMPANY
MERCK RESEARCH LABORATORIES
NATIONAL DAIRY COUNCIL
PARKE-DAVIS PHARMACEUTICAL RESEARCH
PFIZER INC.
PROCTER AND GAMBLE COMPANY
ROSS LABORATORIES
WYETH-AYERST RESEARCH

P R O G R A M

Tuesday, March 8

6:30 p.m.
WINE TASTING
Fairway Deck

8:00 p.m.
DINNER
with remarks by Fred Kern, Jr.
Silverado East

Wednesday, March 9

7:30 - 9:00 a.m.
BREAKFAST BUFFET

9:00 a.m. - 12:30 p.m.
INTRODUCTION
Roger A. Davis

SCIENTIFIC SESSION I:
STEROLS
Leader: *Peter Edwards*

Transcriptional Regulation of
HMG-CoA Reductase
Timothy Osborne

Trasncriptional Regulation of the LDL Receptor
Xiaodong Wang

The Regulated Degradation of HMG-CoA
Reductase in S. Cerevisiae by a Novel,
Non-Lysosomal Pathway
Randolph Hampton

The Farnesylation Dependent Maturation of
Prelamin A
Michael Sinensky

6:00 - 7:30 p.m.
DINNER

7:30 - 10:30 p.m.
SCIENTIFIC SESSION II:
GENETICS
Leader: *Aldons J. Lusis*

Fatty Liver Dystrophy:
A Mutation Affecting Triglyceride Metabolism
Karen Reue

Apo E and Alzheimer's Disease
Karl Weisgraber

Genetic Studies of NIDDM in Pima Indians
Clifton Bogardus

Linkage Analysis of Quantitative Traits
Associated with Atherosclerosis
Jerome Rotter

Thursday, March 10

7:30 - 9:00 a.m.
BREAKFAST BUFFET

9:00 a.m. - 12:30 p.m.
SCIENTIFIC SESSION III:
APO B
Leader: *Stephen G. Young*

Human Apo-B Transgenic Mice
Stephen G. Young

Translocation of Apo B
Jean Vance

Abetalipoproteinemia
John Wetterau

Apo B Secretion in Non-Hepatic Cells
Haya Herscovitz

6:00 - 7:30 p.m.
DINNER

7:30 - 10:30 p.m.
SCIENTIFIC SESSION IV:
GENE EXPRESSION
Leader: *Linda K. Curtiss*

Transcriptional Control
of the Macrophage Scavenger Receptor
Christopher Glass

Molecular Cloning and
Functional Expression of MCP-1 Receptors
Israel Charo

L35 cells, a Culture Equivalent of Liver In Vivo
John Trawick

Friday, March 11

7:30 - 9:00 a.m.
BREAKFAST BUFFET

9:00 a.m. - 12:30 p.m.
SCIENTIFIC SESSION V:
LIPOPROTEIN METABOLISM AND UPTAKE
Leader: *Skaidrite Krisans*

Role of Hepatic Lipase in Hepatic Uptake of
Chylomicron Remnants
Richard J. Havel

Analysis of Lipoprotein Receptors in the Mouse
Joachim Herz

Apo A-I Conformation and Cholesterol
Transfers
Yves L. Marcel

***

Scientific Sessions will be held in the Silverado West.

THE 1995 DEUEL CONFERENCE ON LIPIDS

1 August 1994

Replaced E 5/1/95 letter
RJ
Rec'd 8/9/94

George A. Hashim, Ph.D.
Associate Research Director
Council for Tobacco Research - USA, Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

The 1995 Deuel Conference on Lipids has been set for March 7-10, 1995 in Napa, California.

The program is being organized by Dr. Alan Chait of the University of Washington with the following tentative proposed topics:

1. *Lipases and esterases*

Mutations in lipoprotein lipase: hormone sensitive lipase in macrophages; platelet activating factor acetyl hydrolase and paraoxonase

2. *Oxidative processes in atherosclerosis*

Cellular mechanisms of LDL oxidation; antioxidants - structure and function; gene regulation by reactive oxygen species and oxidized lipids

3. *Proteoglycan-lipoprotein interactions*

Proteoglycans in the extracellular matrix of the artery wall; glycosaminoglycans-lipoprotein lipase interaction; role of cell surface glycosaminoglycans in lipoprotein receptor interactions

4. *New animal models for the study of atherosclerosis*

Cholesterol ester transfer protein transgenic mice; transgenic rabbits; homologous recombination to achieve cytokine deficiency; use of animal models for arterial wall imaging.

5. *Nutrition*

Vitamin E and disease states; transfatty acids and atherosclerosis; nutrients in gene regulation; genetics of dietary responsiveness

6. *HDL*

Rare HDL apolipoproteins; HDL binding proteins; HDL species involved in cholesterol efflux

#4119-WINTER NEUROPEPTIDE CONF.,
NEUROPEPTIDES, BRECKENRIDGE, CO
1/28-31/95

Stop placed on

Replacement check
sent to
Ms Debra Edwards
Conference Coordinator
Winter Neuropeptide Conf
PO Box 7518
Breckenridge, Co 80424

370116
8/29/94

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Bibie M. Chronwall, Ph.D.
Finance Chairman, WNPC
SBLS/SSB
Univesity of Missouri-Kansas City
2411 Holmes
Kansas City, MO 64108

Subject: Winter Neuropeptide Conference
Neuropeptides, Learning and Memory
Date: January 28-31, 1995
Location: Breckenridge, CO

Re: #4119

Dear Dr. Chronwall:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to Winter Neuropeptide Conference, is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: Auditors, ROK, LP,
Administrative Actions

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

August 24, 1994

Bibie M. Chronwall, Ph.D.
Finance Chairman, WNPC
SBLS/SSB
Univesity of Missouri-Kansas City
2411 Holmes
Kansas City, MO 64108

Re: #4119

Subject: Winter Neuropeptide Conference
Neuropeptides, Learning and Memory
Date: January 28-31, 1995
Location: Breckenridge, CO

Dear Dr. Chronwall:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to Winter Neuropeptide Conference, is enclosed for your attention.

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file

Bcc: Auditors, ROK, LP,
Administrative Actions

WINTER NEUROPEPTIDE CONFERENCE

Chairman
Fleur Strand
Biology Department
New York University
Washington Square
New York, NY 10003
(212) 998-8275

Treasurer and Facilities Chairman
Curt A. Sandman
Department of Psychiatry
University of California, Irvine
State Developmental Research Institutes
2501 Harbor Boulevard
Costa Mesa, CA 92626
(714) 957-5435

Finance Chariman
Bible Chronwall
SBLS / SSB
University of Missouri - Kansas City
2411 Holmes
Kansas City, MO 64108
(816) 276-1868

Program Chairman
Bill Beckwith
1520 Royal Palm Square Boulevard
Suite 350
Ft. Myers, FL 33919
(813) 278-3443

Conference Coordinator
Debra Edwards
P.O. Box 7518
Breckenridge, CO 80424
(303) 453-5970

Kansas City, Missouri

July 20, 1994

94-30
95-11
JK

Dr. George A. Hashim
Council for Tobacco Research
900 3rd Avenue
New York, NY 100221

Dear Dr. Hashim:

As an important developer of pharmaceutical and biological products, you may be well aware of the implications of the growing field of neuropeptide research. The Winter Neuropeptide Conference is a meeting designed to stimulate neuropeptide research and allow a multidisciplinary discussion of aspects of neuropeptide functions. The conference in 1995 will be our 16th meeting. Renowned Dr. David De Wied from the Rudolf Magnus Institute of the University of Utrecht will be plenary speaker. His topic will be "Neuropeptides, Learning and Memory".

The planned symposia will highlight advances in major areas of neuropeptide research; the speakers and their topics are listed in the enclosed program. In addition, 30-40 posters on peptide-related topics will be presented. A section of the poster session will be devoted to young investigators presenting their own research. The WNPC provides an excellent opportunity for young and established researchers from the industry, the clinic and academe to exchange ideas in a stimulating environment.

Your company has very generously supported our conference in previous years and to ensure the success of this year's meeting, we are asking you for continued financial help. Your support is more needed than ever this year. All contributions will be greatly appreciated. Please direct checks to Dr. Curt Sandman, our conference treasurer, at the address listed on the left. This office also has our tax exempt number.

Members of your research team are cordially invited to attend the conference, which will be held in Breckenridge, Colorado, January 28-31, 1995. Please contact the conference coordinator for the registration forms.

Since we are asking you for support - is there anything else than acknowledge you support in the printed program that we can do for you in immediate return? We will be happy to display company advertisements and distribute materials to participants or whatever else you may suggest. Please call me to make arrangements for your special needs; ***we want to make it profitable for you to support us.***

Thank you in advance for your kind consideration.

Sincerely,

Bibie M. Chronwall

Bibie M. Chronwall, Ph.D.
Finance Chairman WNPC

TENTATIVE SYMPOSIA FOR 16th ANNUAL WINTER NEUROPEPTIDE CONFERENCE

PLENARY SPEAKER

"Neuropeptides, Learning and Memory"

Dr. David De Wied

PANEL: "Gut Neuropeptides: Motilin." Theo Peeters, Katholieke Universiteit Leuven, Department of Medical Research, Gut Hormone Laboratory, Gasthuisberg O & N, B-3000 Leuven, Belgium

"Motilin and the regulation of gastrointestinal motility"

"Characterization and localization of the motilin receptor"

"Interaction of motilin with the enteric nervous system"

"Development and therapeutic applications of motilin agonists"

"Presence in the brain and central effects of motilin"

PANEL: "Insect Neuropeptides." Ronald J. Nachman, Food Animal Protection Research Laboratory, United States Department of Agriculture, Agriculture Research Service, Route 5, Box 810 College Station TX 77845

"Insect Neuropeptides: An Overview." Peter Masler, Insect Hormone Laboratory, U.S. Department of Agriculture, Beltsville, MD

"Neuropeptides (including CRF-related) Implicated in the Control of Diuresis in Insects.", Geoff Coast, Department of Biology, University of London, UK

"Insect Metabolic Neuropeptides." Larry Keeley, Department of Entomology, Texas A&M University, College Station, TX

"Insect Pheromone Biosynthesis Activating Neuropeptides." Peter Teal, Insect Attractants, Behavior and Basic Biology Research Laboratory, U.S. Department of Agriculture, Gainesville, FL

"Active Conformation and Mimetic Agonist Development of Insect Neuropeptides." Ronald Nachman, Food Animal Protection Research Laboratory, United States Department of Agriculture, Agriculture Research Service, Route 5, Box 810, College Station TX 77845

PANEL: "Central Vasoactive Peptides: Where, When, and Why Are They Secreted?" Mariana Morris, Bowman Gray School of Medicine of Wake Forrest University, Winston-Salem NC 27157

"The Renin Transgenic Rat: A Model for the Study of Central Peptide Dysfunction." Mariana Morris, Bowman Gray School of Medicine of Wake Forrest University, Winston-Salem NC 27157

"Functional Role of Centrally Released Vasopressin and Oxytocin?" Michael Callahan, Bowman Gray School of Medicine of Wake Forrest University, Winston-Salem NC 27157

"Neurochemical Control of Central Peptide synthesis and Secretion Using a Hypothalamic Tissue Culture Movel, Celia D. Sladek, University of Health Sciences, the Chicago Medical School, North Chicago, IL 60064-3095

"Brain Angiotensin: Does if Regulate Cardiovascular and Fluid Balance?" Allen Kim Johnson, Department of Psychology, Iowa City, IA 52242

PANEL: "Brain Circumventricular Organs (CVOs): Portals for Peptides." Allen Kim Johnson, Department of Psychology, Iowa City, IA 52242

"The Actions of Circulating Peptides on CVOs on the Lamina Terminalis (i.e., SFO and OVLT) in Body Fluid and Cardiovascular Homeostasis." S.L. Bealer, University of Tennessee

"The Role of the Periventricular Anteroventral Third Ventricle in the Mediation of Sympathetic Nerve Activity Induced by Insulin." M. Muntzel, City University of New York

"The Actions of Vasopressin on the Area Postrema in Normal and Pathological (Hypertension) Regulation of Arterial Blood Pressure E. Hasser, University of Missouri

"The Role of the Area Postrema in Energy and Mineral Metabolism." G.L. Edwards, University of Georgia

"The Use of Cultured Circumventricular Organ Neurons for an in vitro Analysis of Peptide Action." Meredith Hay, University of Texas Health Sciences Center at San Antonio

PANEL: "Excitory Effects of Corticotropin Releasing Hormone (CRH) on Immature Neurons: in vivo, in vitro, Neuropathology and Implications." Charles E. Ribak, University of California, Irvine, Department of Anatomy and Neurobiology College of Medicine, Irvine, CA 92717

"CRH-induced seizures in immature rats: in vivo effects of synthetic neuropeptide and of alterationsin endogenous peptide production." Tallie Z. Baram, USC Children's Hospital, Los Angeles, CA

"In vitro effects of CRH in the immature vs. mature hippocampal slice preparation -- potential mechanisms." F. Edward Dudek, Colorado State University, Fort Collins, CO

"Synaptic reorganization and neuronal death secondary to CRF-induced status epilepticus in infant rats." Charles E. Ribak, University of California, Irvine, Department of Anatomy and Neurobiology, College of Medicine, Irvine, CA 92717

PANEL: "Melanocortin Receptors and Functional Anatagonism in the Pro-opiomelanocortin Neuron System." Jeffrey Tatro, Tufts University School of Medicine and New England Medical Center Hospitals

"Functional Organization of the Melanocortinergic Neuron-receptor System." Jeff Tatro, Tufts University School of Medicine and New England Medical Center Hospitals

"Molecular Biology of the Melanocortin Receptor Family." Linda Roselli-Rehfuss, Clinical Research Institute of Montreal

"Functional Antagonism between Melanocortins, Endorphins and Cytokines in Neuroendocrine Regulation." Sharon Wardlaw, College of Physicians and Surgeons, Columbia University

"The Molecular Genetics and Biology of *Agouti*." Gregory S. Barsh, Howard Hughes Medical Institute, Stanford University Medical Center

WINTER NEUROPEPTIDE CONFERENCE

Chairman
Fleur Strand
Biology Department
New York University
Washington Square
New York, NY 10003
(212) 998-8275

Treasurer and
Facilities Chairman
Curt A. Sandman
Department of Psychiatry
University of California, Irvine
State Developmental Research Institutes
2501 Harbor Boulevard
Costa Mesa, CA 92626
(714) 957-5435

Finance Chariman
Bible Chronwall
SBLS / SSB
University of Missouri - Kansas City
2411 Holmes
Kansas City, MO 64108
(816) 276-1868

Program Chairman
Bill Beckwith
1520 Royal Palm Square Boulevard
Suite 350
Ft. Myers, FL 33919
(813) 278-3443

Conference Coordinator
Debra Edwards
P.O. Box 7518
Breckenridge, CO 80424
(303) 453-5970

Kansas City
July 15, 1994

Dear Dr. Hashim:

I enjoyed seeing you last year in DC at the Neuroscience meeting and to have had the opportunity to thank you in person for the Council's generous support of WNPC. I trust you will stay with us this year too. Last year was lean and we started to use our small savings. We really need and value your help.

Sincerely

Bibel M. Chronwall

From the desk of

LORRAINE POLLICE

3/16/95

Dear Debra,

As discussed, I am pleased to enclose a replacement check covering our contribution to the '95 conference

Lorraine

The Council For Tobacco Research - U.S.A., Inc.
- 900 Third Avenue, New York, N. Y. 10022

#4121-FASEB SUMMER RESEARCH CONF.
CYTOKINE & LIPID MEDIATORS,
Saxton River, VT 7/8-13/95

3018
4313
4

HARVARD MEDICAL SCHOOL

BRIGHAM AND WOMEN'S HOSPITAL

CHARLES N. SERHAN, Ph.D.
Associate Professor of
Medicine (Biochemistry)
Senior Biochemist

HEMATOLOGY-ONCOLOGY DIVISION
Brigham and Women's Hospital
Longwood Medical Research Center
221 Longwood Avenue
Boston, Mass. 02115
Tel.: (617) 732-5875 (Office)
Tel.: (617) 732-5888 (Laboratory)
Fax: (617) 739-3324

September 14, 1994

George A. Hashim, Ph.D.
The Council for Tobacco Research
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

Thank you very much for your letter of August 24 and contribution to the FASEB Summer Research Conference entitled "Cytokines and Lipid Mediators" scheduled for July 8-13, 1995.

I have sent a copy of your letter to Adele Hewitt at FASEB, who is handling the account. Her office will also supply you with a written confirmation of the Council for Tobacco Research contribution to the meeting. I will also take this opportunity to let you know that the $1000 contribution will be used as you request to defray the cost of participants from the academic arena. It is most likely that we will use these funds to sponsor young investigators to attend the meeting. I can assure you that your contribution will not be used to reimburse expenses incurred by participants from the industrial sector.

Again, thank very much for your contribution and for your interest in this scientific meeting.

Sincerely yours,

Charles N. Serhan

/mhs

FASEB

FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY

The American Physiological Society
American Society for Biochemistry and Molecular Biology
American Society for Pharmacology and Experimental Therapeutics
American Society for Investigative Pathology
American Institute of Nutrition
The American Association of Immunologists
The American Society for Cell Biology
Biophysical Society
American Association of Anatomists

MICHAEL J. JACKSON
Executive Director

JOHN R. RICE, C.P.A.
Comptroller

OFFICE OF SCIENTIFIC MEETINGS AND CONFERENCES
GERI GOODENOUGH
Director

File Conference Support
9/8/94

September 2, 1994

George A. Hashim, Ph.D.
Associate Research Director
The Council for Tobacco Research-U.S.A., Inc.
900 Third Ave.
New York, NY 10022

Dear Dr. Hashim:

We are pleased to acknowledge the contribution of $1000 from The Council for Tobacco Research-U.S.A., Inc. in support of the FASEB Summer Research Conference, "Cytokines and Lipid Mediators in Cell Function," to be held July 8-13, 1995 in Saxtons River, Vermont.

The Federation and scientists who participate in these conferences appreciate your support in the advancement of scientific communication. The funds will be used by the chairperson of the conference, Dr. Charles N. Serhan, to defray the travel and registration expenses for some of the speakers.

We extend an invitation to the scientists of your organization who are interested in applying to any of the FASEB Summer Research Conferences.

The Federation of American Societies for Experimental Biology is accredited by the Accreditation Council for Continuing Medical Education to sponsor CME activities for physicians. In order to comply with the guidelines set forth by the ACCME, the following terms and conditions apply to the educational grant you have provided.

1. **Statement of Purpose:** Program is for scientific purposes only and will not promote the company's products, directly or indirectly.

9650 Rockville Pike • Bethesda, Maryland 20814-3998
Telephone 301-530-7010 • FAX 301-530-7014

2. **Control of Content & Selection of Presenters & Moderators:** Sponsor is responsible for control of content and selection of presenters and moderators. The company agrees not to direct the content of the program. The company, or agents, will respond only to Sponsor initiated requests for suggestions of presenters or sources of possible presenters.

3. **Disclosure of Financial Relationships:** Sponsor will ensure meaningful disclosure to the audience, at the time of the program, of (a) Company funding and (b) any significant relationship between the Sponsor and the Company (e.g., grant recipient) or between individual speakers or moderators and the Company.

4. **Involvement in Content:** There will be no "scripting", emphasis, or direction of content by the Company or its agents.

5. **Ancillary Promotional Activities:** No promotional activities will be permitted.

Please express to the appropriate officials our appreciation for your generous support of this conference.

Sincerely,

Adele F. Hewitt

Adele F. Hewitt
Conference Coordinator
FASEB Summer Research Conferences

fundlet.1155a

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

Date: August 24, 1994

Dr. Charles N. Serhan
Hematology-Oncology Division
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115

Re: #4121

Subject: FASEB Summer Research Conference
Cytokine and Lipid Mediators
Location: Vermont Academy in Saxton River, VT
Date: July 8-13, 1995

Dear Dr. Serhan:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to FASEB, was forwarded to FASEB together with a copy of this letter

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file
FASEB

BCC: Auditors, ROK, LP,
Administrative Actions

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

GEORGE A. HASHIM, PH.D.
ASSOCIATE RESEARCH DIRECTOR

Date: August 24, 1994

Dr. Charles N. Serhan
Hematology-Oncology Division
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115

Re: #4121

Subject: FASEB Summer Research Conference
Cytokine and Lipid Mediators
Location: Vermont Academy in Saxton River, VT
Date: July 8-13, 1995

Dear Dr. Serhan:

The Scientific Director and CTR's staff have discussed your request for partial support of the conference named above. The program contains topics of interest to the Council, and the list of speakers ensures the scientific quality of the meeting. I am pleased to inform you that we will make a contribution of $1,000 to help defray, in part, the costs of the conference. A check for the noted amount, payable to FASEB, was forwarded to FASEB together with a copy of this letter

It would assist in our record-keeping if we could have a written acknowledgment of the contribution. We request only that these funds not be used to reinburse expenses incurred by participants from the industrial sector.

Sincerely yours,

George A. Hashim

cc; Dr. H. McAllister
file
FASEB

BCC: Auditors, ROK, LP,
Administrative Actions

4/11/94
Notified Dr. Serhan
He will hear from
us in the fall
S

OK

HARVARD MEDICAL SCHOOL

BRIGHAM AND WOMEN'S HOSPITAL

CHARLES N. SERHAN, PH.D.
Associate Professor of
Medicine (Biochemistry)
Senior Biochemist

HEMATOLOGY-ONCOLOGY DIVISION
Brigham and Women's Hospital
75 Francis Street
Boston, Mass. 02115
Tel. (617) 732-5875 (Office)
Tel. (617) 732-5888 (Laboratory)
Fax: (617) 739-3324

April 1, 1994

July → 1995

George A. Hashim, Ph.D.
Associate Research Director
Council for Tobacco Research-USA Inc.
900 Third Avenue
New York, NY 10022

Dear Dr. Hashim:

I have the pleasure of serving as Chairperson for the third biennial FASEB (Federation of American Societies for Experimental Biology) Summer Research Conference on Cytokines and Lipid Mediators, which will be held July 8-13, 1995 at the Vermont Academy in Saxtons River, Vermont. This conference will tentatively have sessions on the following topics:

1. Molecular Biology of Enzymes in Lipid Mediators
2. Regulation of Inflammatory Processes
3. Cytokine Receptors and Function
4. Disease Models and Tissue Injury
5. Lipases in Mediator Release
6. Eicosanoids in Cell Function
7. Lipid Mediators, Receptors and Signal Transduction
8. Cell-Cell Interactions
9. Regulation of Lipid Mediator Production and Signal Transduction/Inhibitor Design in Signal Transduction

(See enclosed tentative program and timetable.)

The Co-Chair of this conference is Dr. Christina Leslie of the National Jewish Hospital, Denver, Colorado. Approximately 55 participants from North America, Europe, Japan and Scandinavia have tentatively accepted invitations to speak, depending on financial support in many cases. I have enclosed a tentative program in order to give you a more precise feeling for the high quality and interdisciplinary nature of the meeting. This meeting is particularly useful and important because it is the only conference of this type devoted to the integration of these topics. Recent progress has been rapid and exciting, particularly as the potential new clinical relevance of basic work in the biosynthesis of lipid mediators and the regulation and interactions with cytokines.

I am trying to raise at least $65,000 for partial support of participants' travel and registration expenses (approximately $500 on the average for travel and $430 for registration, which will cover room and board). In the case of West Coast travelers and those joining us from Europe and Japan, travel can be as high as $1,000. Thus, I am writing you to inquire about a possible financial contribution.

Senior invited speakers as well as junior investigators will be eligible for support. The conference will be advertised by FASEB to their entire membership, as well as to various journals and society letters, including Cell, Science, and the FASEB Journal. It is expected that a large number of people will apply. The meeting has been very successful in previous years. Attendance is limited to approximately 155 individuals, including speakers. It is important to involve young investigators and women scientists working in this area in such a meeting for obvious reasons, but in many cases resources are limited.

If you are interested in more details about this meeting, please contact myself or Dr. Christina Leslie. I and the other conferees will greatly appreciate any financial help you can give us. Thank you in advance for your time in this matter.

Sincerely,

Charles

Charles N. Serhan

/mhs
Encl.

P.S. Checks should be annotated "Cytokines and Lipid Mediators '95" and made payable to:

FASEB Summer Research Conferences
9650 Rockville Pike
Bethesda, MD 20814

All contributors will be acknowledged in the final program.